Advertisement

Pathogenesis of Type 2 Diabetes Mellitus

  • Ralph A. DeFronzo
Reference work entry
Part of the Endocrinology book series (ENDOCR)

Abstract

  • Type 2 diabetes is characterized by multiple pathophysiologic abnormalities which collectively have been referred to as the Ominous Octet:
    • Muscle insulin resistance → reduced glucose uptake

    • Hepatic insulin resistance → excessive glucose production

    • Adipocyte insulin resistance → accelerated lipolysis and elevated circulating levels of FFA and insulin-resistance provoking adipocytokines

    • Progressive β-cell failure and apoptosis

    • Increased alpha cell secretion of glucagon and increased hepatic sensitivity to glucagon

    • Reduced incretin effect due to beta cell resistance to GLP-1 and GIP

    • Increased renal glucose production

    • Elevated renal tubular glucose reabsorption

    • Brain insulin resistance and altered neurotransmitter dysfunction leading to impaired appetite suppression and weight gain.

  • Insulin resistance in muscle and liver are the earliest detectable abnormalities in the natural history of type 2 diabetes.

  • With time, progressive β-cell failure ensues and, in the presence of insulin resistance, individuals progress from normal glucose tolerance to impaired glucose tolerance to overt type 2 diabetes.

Keywords

Pathophysiology of T2DM Insulin resistance Beta cell failure Liver, muscle, adipocyte Ominous octet 

References

  1. Abdul-Ghani M, DeFronzo RA. Fasting hyperglycemia impairs glucose- but not insulin-mediated suppression of glucagon secretion. J Clin Endocrinol Metab. 2007;92(5):1778–84.PubMedCrossRefGoogle Scholar
  2. Abdul-Ghani MA, DeFronzo RA. Mitochondrial dysfunction, insulin resistance, and type 2 diabetes mellitus. Curr Diab Rep. 2008;8(3):173–8.PubMedCrossRefGoogle Scholar
  3. Abdul-Ghani MA, DeFronzo RA. Plasma glucose concentration and prediction of future risk of type 2 diabetes. Diabetes Care. 2009;32:S194–S8.PubMedPubMedCentralCrossRefGoogle Scholar
  4. Abdul-Ghani M, Jenkinson C, Richardson D, et al. Insulin secretion and insulin action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study (VAGES). Diabetes. 2006a;55:1430–5.PubMedCrossRefGoogle Scholar
  5. Abdul-Ghani M, Tripathy D, DeFronzo RA. Contribution of beta cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care. 2006b;29:1130–9.PubMedCrossRefGoogle Scholar
  6. Abdul-Ghani MA, Williams K, DeFronzo R, Stern M. Risk of progression to type 2 diabetes based on relationship between postload plasma glucose and fasting plasma glucose. Diabetes Care. 2006c;29(7):1613–8.PubMedCrossRefGoogle Scholar
  7. Abdul-Ghani MA, Matsuda M, Sabbah M, et al. The relative contribution of insulin resistance and beta cell failure to the transition from normal to impaired glucose tolerance varies in different ethnic groups. Diabetol Metab Syndr. 2007a;1:105–12.CrossRefGoogle Scholar
  8. Abdul-Ghani MA, Williams K, DeFronzo RA, Stern M. What is the best predictor of future type 2 diabetes? Diabetes Care. 2007b;30(6):1544–8.PubMedCrossRefGoogle Scholar
  9. Abdul-Ghani MA, Muller FL, Liu Y, et al. Deleterious action of FA metabolites on ATP synthesis: possible link between lipotoxicity, mitochondrial dysfunction, and insulin resistance. Am J Physiol Endocrinol Metab. 2008;295(3):E678–85.PubMedCrossRefGoogle Scholar
  10. Abdul-Ghani MA, Lyssenko V, Tuomi T, DeFronzo RA, Groop L. Fasting versus postload plasma glucose concentration and the risk for future type 2 diabetes: results from the Botnia study. Diabetes Care. 2009a;32(2):281–6.PubMedPubMedCentralCrossRefGoogle Scholar
  11. Abdul-Ghani MA, Jani R, Chavez A, Molina-Carrion M, Tripathy D, DeFronzo RA. Mitochondrial reactive oxygen species generation in obese non-diabetic and type 2 diabetic participants. Diabetologia. 2009b;52(4):574–82.PubMedCrossRefGoogle Scholar
  12. Abdul-Ghani MA, Norton L, DeFronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev. 2011;32:515–31.PubMedCrossRefGoogle Scholar
  13. Abdul-Ghani MA, DeFronzo RA, Norton L. Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30–50% of filtered glucose load in humans. Diabetes. 2013;62(10):3324–8.PubMedPubMedCentralCrossRefGoogle Scholar
  14. Abdul-Ghani MA, Norton L, DeFronzo RA. Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus. Am J Physiol Renal Physiol. 2015;309(11):F889–900.PubMedPubMedCentralCrossRefGoogle Scholar
  15. Adams JM 2nd, Pratipanawatr T, Berria R, et al. Ceramide content is increased in skeletal muscle from obese insulin-resistant humans. Diabetes. 2004;53(1):25–31.PubMedCrossRefGoogle Scholar
  16. Ahlqvist E, Ahluwalia TS, Groop L. Genetics of type 2 diabetes. Clin Chem. 2011;57:241–54.PubMedCrossRefGoogle Scholar
  17. Ahrén B, Taborsky GJ. Beta-cell function and insulin secretion. In: Porte D, Sherin RS, Baron A, editors. Ellenberg and Rifkin’s diabetes mellitus. New York: McGraw Hill; 2003. p. 43–65.Google Scholar
  18. Alatrach M, Agyin C, Adams J, DeFronzo RA, Abdul-Ghani A. Decreased basal heaptic glucose uptake in subjects with impaired fasting glucose. Diabetologia. 2017;60(7):1325–32.PubMedCrossRefPubMedCentralGoogle Scholar
  19. Alcolado JC, Laji K, Gill-Randall R. Maternal transmission of diabetes. Diabet Med. 2002;19(2):89–98.PubMedCrossRefGoogle Scholar
  20. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2008;31(Suppl 1):S65–0.Google Scholar
  21. Andreelli F, Laville M, Ducluzeau P-H, et al. Defective regulation of phosphatidylinositol-3-kinase gene expression in skeletal muscle and adipose tissue of non-insulin-dependent diabetes mellitus patients. Diabetologia. 1999;42:358–64.PubMedCrossRefGoogle Scholar
  22. Andreozzi F, D’Alessandris C, Federici M, et al. Activation of the hexosamine pathway leads to phosphorylation of insulin receptor substrate-1 on Ser307 and Ser612 and impairs the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin insulin biosynthetic pathway in RIN pancreatic beta-cells. Endocrinology. 2004;145:2845–57.PubMedCrossRefGoogle Scholar
  23. Andrews WJ, Vasquez B, Nagulesparan M, et al. Insulin therapy in obese, non-insulin-dependent diabetes induces improvements in insulin action and secretion that are maintained for two weeks after insulin withdrawal. Diabetes. 1984;33:634–42.PubMedCrossRefGoogle Scholar
  24. Arkan MC, Hevener AL, Greten FR, et al. IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med. 2005;11(2):191–8.PubMedCrossRefGoogle Scholar
  25. Arner P, Pollare T, Lithell H. Different etiologies of type 2 (non-insulin-dependent) diabetes mellitus in obese and non-obese subjects. Diabetologia. 1991;34:483–7.PubMedCrossRefGoogle Scholar
  26. Bajaj M, DeFronzo RA. Metabolic and molecular basis of insulin resistance. J Nucl Cardiol. 2003;10:311–23.PubMedCrossRefGoogle Scholar
  27. Bajaj M, Pratipanawatr T, Berria R, et al. Free fatty acids reduce splanchnic and peripheral glucose uptake in patients with type 2 diabetes. Diabetes. 2002;51(10):3043–8.PubMedCrossRefGoogle Scholar
  28. Bajaj M, Suraamornkul S, Pratipanawatr T, et al. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes. 2003;52(6):1364–70.PubMedCrossRefGoogle Scholar
  29. Bajaj M, Suraamornkul S, Kashyap S, Cusi K, Mandarino L, DeFronzo RA. Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type 2 diabetes. J Clin Endocrinol Metab. 2004;89(9):4649–55.PubMedCrossRefGoogle Scholar
  30. Bajaj M, Suraamornkul S, Romanelli A, et al. Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty acyl-CoAs and insulin action in type 2 diabetic patients. Diabetes. 2005;54(11):3148–53.PubMedCrossRefGoogle Scholar
  31. Bajaj M, Baig R, Suraamornkul S, et al. Effects of pioglitazone on intramyocellular fat metabolism in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2010;95(4):1916–23.PubMedPubMedCentralCrossRefGoogle Scholar
  32. Banjeri MA, Lebovitz HE. Insulin action in black Americans with NIDDM. Diabetes Care. 1992;15:1295–302.CrossRefGoogle Scholar
  33. Baron AD, Schaeffer L, Shragg P, Kolterman OG. Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. Diabetes. 1987;36:274–83.PubMedCrossRefGoogle Scholar
  34. Bauer PV, Duca FA. Targeting the gastrointestinal tract to treat type 2 diabetes. J Endocrinol. 2016;230(3):R95–R113.PubMedCrossRefGoogle Scholar
  35. Bays H, Mandarino L, DeFronzo RA. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonsits provide a rational therapeutic approach. J Clin Endocrinol Metab. 2004;89:463–78.PubMedCrossRefGoogle Scholar
  36. Bays HE, Gonzalez-Campoy JM, Bray GA, et al. Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert Rev Cardiovasc Ther. 2008;6:343–68.PubMedCrossRefGoogle Scholar
  37. Beck-Nielsen H, Nielsen OH, Pedersen O, et al. Insulin action and insulin secretion in identical twins with MODY: evidence for defects in both insulin action and insulin secretion. Diabetes. 1988;37:730–5.PubMedCrossRefGoogle Scholar
  38. Befroy DE, Petersen KF, Dufour S, et al. Impaired mitochondrial substrate oxidation in muscle of insulin-resistant offspring of type 2 diabetic patients. Diabetes. 2007;56(5):1376–81.PubMedPubMedCentralCrossRefGoogle Scholar
  39. Belfort R, Mandarino L, Kashyap S, et al. Dose-response effect of elevated plasma free fatty acid on insulin signaling. Diabetes. 2005;54(6):1640–8.CrossRefGoogle Scholar
  40. Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006;355(22):2297–307.PubMedCrossRefGoogle Scholar
  41. Bell G, Kayano T, Buse JB, et al. Molecular biology of mammalian glucose transporters. Diabetes Care. 1990;13:198–200.PubMedCrossRefGoogle Scholar
  42. Bell GI, Zian K, Newman M, et al. Gene for non-insulin-dependent diabetes mellitus (maturity-onset diabetes of the young subtype) is linked to DNA polymorphism on human chromosome 20q. PNAS. 1991;88:1484–8.PubMedCrossRefGoogle Scholar
  43. Benninger RK, Piston DW. Cellular communication and heterogeneity in pancreatic islet insulin secretion dynamics. Trends Endocrinol Metab. 2014;25(8):399–406.PubMedPubMedCentralCrossRefGoogle Scholar
  44. Bergman RN. Lilly lecture 1989. Toward physiological understanding of glucose tolerance. Minimal-model approach. Diabetes. 1989;38:1512–27.PubMedCrossRefGoogle Scholar
  45. Bergman RN. Non-esterified fatty acids and the liver: why is insulin secreted into the portal vein? Diabetologia. 2000;43:946–52.PubMedCrossRefGoogle Scholar
  46. Bergman RN, Finegood DT, Kahn SE. The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes. Eur J Clin Investig. 2002;32:35–45.CrossRefGoogle Scholar
  47. Bertola A, Ciucci T, Rousseau D, et al. Identification of adipose tissue dendritic cells correlated with obesity-associated insulin-resistance and inducing Th17 responses in mice and patients. Diabetes. 2012;61(9):2238–47.PubMedPubMedCentralCrossRefGoogle Scholar
  48. Bevilacqua S, Bonadonna R, Buzzigoli G, et al. Acute elevation of free fatty acid levels leads to hepatic insulin resistance in obese subjects. Metabolism. 1987;36(5):502–6.PubMedCrossRefGoogle Scholar
  49. Bezy O, Tran TT, Pihlajamaki J, et al. PKCdelta regulates hepatic insulin sensitivity and hepatosteatosis in mice and humans. J Clin Invest. 2011;121(6):2504–17.PubMedPubMedCentralCrossRefGoogle Scholar
  50. Bjorbaek C, Echward SM, Hubricht P, et al. Genetic variants in promoters and coding regions of the muscle glycogen synthase and the insulin-responsive GLUT4 genes in NIDDM. Diabetes. 1994;43:976–83.PubMedCrossRefGoogle Scholar
  51. Bjorbaek C, Fik TA, Echward SM, et al. Cloning of human insulin-stimulated protein kinase (ISPK-1) gene and analysis of coding regions and mRNA levels of the ISPK-1 and the protein phosphatase-1 genes in muscle from NIDDM patients. Diabetes. 1995;44:90–7.PubMedCrossRefGoogle Scholar
  52. Blandino G, Inturri R, Lazzara F, Di Rosa M, Malaguarnera L. Impact of gut microbiota on diabetes mellitus. Diabetes Metab. 2016;42(5):303–15.PubMedCrossRefGoogle Scholar
  53. Blazquez E, Velazquez E, Hurtado-Carneiro V, Ruiz-Albusac JM. Insulin in the brain: its pathophysiological implications for States related with central insulin resistance, type 2 diabetes and Alzheimer’s disease. Front Endocrinol. 2014;5:161.CrossRefGoogle Scholar
  54. Boden G. Endoplasmic reticulum stress: another link between obesity and insulin resistance/inflammation? Diabetes. 2009;58(3):518–9.PubMedPubMedCentralCrossRefGoogle Scholar
  55. Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Investig. 2002;32(Suppl 3):14–23.CrossRefGoogle Scholar
  56. Boden G, Soriano M, Hoeldtke RD, Owen OE. Counterregulatory hormone release and glucose recovery after hypoglycemia in non-insulin-dependent diabetic patients. Diabetes. 1983;32:1055–9.PubMedCrossRefGoogle Scholar
  57. Boden G, Duan X, Homko C, et al. Increase in endoplasmic reticulum stress-related proteins and genes in adipose tissue of obese, insulin-resistant individuals. Diabetes. 2008;57(9):2438–44.PubMedPubMedCentralCrossRefGoogle Scholar
  58. Bogardus C, Lillioja S, Howard BV, et al. Relationships between insulin secretion, insulin action, and fasting plasma glucose concentration in non-diabetic and noninsulin-dependent subjects. J Clin Investig. 1984;74:1238–46.PubMedCrossRefGoogle Scholar
  59. Bonadonna RC, DeFronzo RA. Glucose metabolism in obesity and type 2 diabetes. Diabetes Metab. 1991;17:112–35.Google Scholar
  60. Bonadonna RC, Del Prato S, Saccomani MP, et al. Transmembrane glucose transport in skeletal muscle of patients with non-insulin-dependent diabetes. J Clin Investig. 1993;92:486–94.PubMedCrossRefGoogle Scholar
  61. Bonadonna RC, Del Prato S, Bonora E, et al. Roles of glucose transport and glucose phosphorylation in muscle insulin resistance of NIDDM. Diabetes. 1996;45:915–25.PubMedCrossRefGoogle Scholar
  62. Bongaerts BW, Rathmann W, Kowall B, et al. Postchallenge hyperglycemia is positively associated with diabetic polyneuropathy: the KORA F4 study. Diabetes Care. 2012;35(9):1891–3.PubMedPubMedCentralCrossRefGoogle Scholar
  63. Bonner-Weir S, Inada A, Yatoh S, et al. Transdifferentiation of pancreatic ductal cells to endocrine beta-cells. Biochem Soc Trans. 2008;36(Pt 3):353–6.PubMedCrossRefGoogle Scholar
  64. Bonora E, Kiechl S, Willeit J, et al. Insulin resistance as estimated by homeostasis model assessment predicts incident symptomatic cardiovascular disease in caucasian subjects from the general population: the Bruneck study. Diabetes Care. 2007;30:318–24.PubMedCrossRefGoogle Scholar
  65. Bosco D, Armanet M, Morel P, et al. Unique arrangement of alpha- and beta-cells in human islets of Langerhans. Diabetes. 2010;59(5):1202–10.PubMedPubMedCentralCrossRefGoogle Scholar
  66. Bouzakri K, Roques M, Gual P, et al. Reduced activation of phosphatidylinositol-3 kinase and increased serine 636 phosphorylation of insulin receptor substrate-1 in primary culture of skeletal muscle cells from patients with type 2 diabetes. Diabetes. 2003;52:1319–25.PubMedCrossRefGoogle Scholar
  67. Bray GA, Glennon JA, Salans LB, et al. Spontaneous and experimental human obesity: effects of diet and adipose cell size on lipolysis and lipogenesis. Metabolism. 1977;26:739–47.PubMedCrossRefGoogle Scholar
  68. Bretherton-Watt D, Ghatei MA, Bloom SR, et al. Altered islet amyloid polypeptide (amylin) gene expression in rat models of diabetes. Diabetologia. 1989;32:881–3.PubMedCrossRefGoogle Scholar
  69. Brunzell JD, Robertson RP, Lerner RL, et al. Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests. J Clin Endocrinol. 1976;46:222–9.CrossRefGoogle Scholar
  70. Bunck MC, Corner A, Eliasson B, et al. Effects of exenatide on measures of beta-cell function after 3 years in metformin-treated patients with type 2 diabetes. Diabetes Care. 2011;34(9):2041–7.PubMedPubMedCentralCrossRefGoogle Scholar
  71. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52(1):102–10.PubMedCrossRefGoogle Scholar
  72. Butterfield WJH, Whichelow MJ. Peripheral glucose metabolism in control subjects and diabetic patients during glucose, glucose-insulin, and insulin sensitivity tests. Diabetologia. 1965;1:43–53.CrossRefGoogle Scholar
  73. Byrne MM, Sturis J, Clement K, et al. Insulin secretory abnormalities in subjects with hyperglycemia due to glucokinase mutations. J Clin Invest. 1994;93(3):1120–30.PubMedPubMedCentralCrossRefGoogle Scholar
  74. Cai D, Yuan M, Frantz DF, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med. 2005;11(2):183–90.PubMedPubMedCentralCrossRefGoogle Scholar
  75. Campbell PJ, Mandarino LJ, Gerich JE. Quantification of the relative impairment in actions of insulin on hepatic glucose production and peripheral glucose uptake in non-insulin dependent diabetes mellitus. Metabolism. 1988;37:15–21.PubMedCrossRefGoogle Scholar
  76. Cani PD, Possemiers S, Van de Wiele T, et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut. 2009;58(8):1091–103.PubMedPubMedCentralCrossRefGoogle Scholar
  77. Cantley JL, Yoshimura T, Camporez JP, et al. CGI-58 knockdown sequesters diacylglycerols in lipid droplets/ER-preventing diacylglycerol-mediated hepatic insulin resistance. Proc Natl Acad Sci U S A. 2013;110(5):1869–74.PubMedPubMedCentralCrossRefGoogle Scholar
  78. Caro JF, Ittoop O, Pories WJ, et al. Studies on the mechanism of insulin resistance in the liver from humans with non-insulin-dependent diabetes. Insulin action and binding in isolated hepatocytes, insulin receptor structure, and kinase activity. J Clin Investig. 1986;78:249–58.PubMedCrossRefGoogle Scholar
  79. Caro JF, Sinha MK, Raju SM, et al. Insulin receptor kinase in human skeletal muscle from obese subjects with and without non-insulin dependent diabetes. J Clin Investig. 1987;79:1330–7.PubMedCrossRefGoogle Scholar
  80. Carpentier A, Mittelman SD, Bergman RN, et al. Prolonged elevation of plasma free fatty acids impairs pancreatic beta-cell function in obese nondiabetic humans but not in individuals with type 2 diabetes. Diabetes. 2000;49:399–408.PubMedCrossRefGoogle Scholar
  81. Cauchi S, Meyre D, Dina C, et al. Transcription factor TCF7L2 genetic study in the French population: expression in human beta-cells and adipose tissue and strong association with type 2 diabetes. Diabetes. 2006;55:2903–8.PubMedCrossRefGoogle Scholar
  82. Cerasi E. Insulin deficiency and insulin resistance in the pathogenesis of NIDDM: is a divorce possible? Diabetologia. 1995;38:992–7.PubMedCrossRefGoogle Scholar
  83. Chang AM, Jakobsen G, Sturis J, et al. The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes. 2003;52:1786–91.PubMedCrossRefGoogle Scholar
  84. Chavez AO, Lopez-Alvarenga JC, Triplitt C, et al. Physiological and molecular determinants of insulin action in the baboon. Diabetes. 2008;57:899–908.PubMedCrossRefGoogle Scholar
  85. Chen YD, Jeng CY, Hollenbeck CB, et al. Relationship between plasma glucose and insulin concentration, glucose production, and glucose disposal in normal subjects and patients with non-insulin-dependent diabetes. J Clin Investig. 1988;82:21–5.PubMedCrossRefGoogle Scholar
  86. Chen X, Iqbal N, Boden G. The effects of free fatty acids on gluconeogenesis and glycogenolysis in normal subjects. J Clin Invest. 1999;103(3):365–72.PubMedPubMedCentralCrossRefGoogle Scholar
  87. Cherrington AD. Control of glucose uptake and release by the liver in vivo. Diabetes. 1999;48:1198–214.PubMedPubMedCentralCrossRefGoogle Scholar
  88. Choi WH, O’Rahilly S, Rees A, et al. Molecular scanning of the insulin-responsive glucose transporter (GLUT 4) gene in patients with non-insulin dependent diabetes mellitus. Diabetes. 1991;40:1712–8.PubMedCrossRefGoogle Scholar
  89. Chou DK, Dull TJ, Russell DS, et al. Human insulin receptors mutated at the ATP-binding site lack protein tyrosine kinase activity and fail to mediate postreceptor effects of insulin. J Biol Chem. 1987;262:1842–7.PubMedGoogle Scholar
  90. Clark A, Wells CA, Buley ID, et al. Islet amyloid, increased α-cells, reduced β-cells and exocrine fibrosis: quantitative changes in the pancreas in type 2 diabetes. Diabetes Res. 1988;9:151–9.PubMedGoogle Scholar
  91. Cline GW, Petersen KF, Krssak M, et al. Impaired glucose transport as a cause of decreased insulin stimulated muscle glycogen synthesis in type 2 diabetes. N Engl J Med. 1999;341:240–6.PubMedCrossRefGoogle Scholar
  92. Clore JN, Stillman J, Sugerman H. Glucose-6-phosphatase flux in vitro is increased in type 2 diabetes. Diabetes. 2000;49:969–74.PubMedCrossRefGoogle Scholar
  93. Cohen P. The Croonian lecture 1999. Identification of a protein kinase cascade of major importance in insulin signal transduction. Philos Trans R Soc Lond Ser B Biol Sci. 1999;354:485–95.CrossRefGoogle Scholar
  94. Coletta DK, Sriwijitkamol A, Wajcberg E, et al. Pioglitazone stimulates AMPK signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo. Diabetologia. 2009;52:723–32.PubMedPubMedCentralCrossRefGoogle Scholar
  95. Consoli A, Nurjhan N, Reilly JJ Jr, et al. Mechanism of increased gluconeogenesis in noninsulin-dependent diabetes mellitus. Role of alterations in systemic, hepatic, and muscle lactate and alanine metabolism. J Clin Investig. 1990;86:2038–45.PubMedCrossRefGoogle Scholar
  96. Copeland RJ, Bullen JW, Hart GW. Cross-talk between GlcNAcylation and phosphorylation: roles in insulin resistance and glucose toxicity. Am J Physiol Endocrinol Metab. 2008;295(1):E17–28.PubMedPubMedCentralCrossRefGoogle Scholar
  97. Cox LA, Mahaney MC, Vandeberg JL, Rogers J. A second-generation genetic linkage map of the baboon (Papio hamadryas) genome. Genomics. 2006;88:274–81.PubMedCrossRefGoogle Scholar
  98. Cox LA, Comuzzie AG, Havill LM, Karere GM, Spradling KD, Mahaney MC, Nathanielsz PW, Nicolella DP, Shade RE, Voruganti S, VandeBerg JL. Baboons as a model to study genetics and epigenetics of human disease. ILAR J. 2013;54:106–21.PubMedPubMedCentralCrossRefGoogle Scholar
  99. Cross D, Alessi D, Vandenheed J, et al. The inhibition of glycogen synthase kinase-3 by insulin or insulin-like growth factor 1 in the rat skeletal muscle cell line L6 is blocked by wortmannin but not rapamycin. Biochem J. 1994;303:21–6.PubMedPubMedCentralCrossRefGoogle Scholar
  100. Cusi K, Maezono K, Osman A, et al. Insulin resistance differentially affects the PI 3-kinase and MAP kinase-mediated signaling in human muscle. J Clin Investig. 2000;105:311–20.PubMedCrossRefGoogle Scholar
  101. Damsbo P, Vaag A, Hother-Nielsen O, et al. Reduced glycogen synthase activity in skeletal muscle from obese patients with and without type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1991;34:239–45.PubMedCrossRefGoogle Scholar
  102. Daniele G, Abdul-Ghani M, DeFronzo RA. What are the pharmacotherapy options for treating prediabetes? Expert Opin Pharmacother. 2014;15(14):2003–18.PubMedCrossRefGoogle Scholar
  103. Dansinger ML, Tatsioni A, Wong JB, Chung M, Balk EM. Meta-analysis: the effect of dietary counseling for weight loss. Ann Intern Med. 2007;147(1):41–50.PubMedCrossRefGoogle Scholar
  104. Davies MJ, Metcalfe J, Gray IP, et al. Insulin deficiency rather than hyperinsulinaemia in newly diagnosed type 2 diabetes mellitus. Diabet Med. 1993;10:305–12.PubMedCrossRefGoogle Scholar
  105. de Alvaro C, Teruel T, Hernandez R, Lorenzo M. Tumor necrosis factor alpha produces insulin resistance in skeletal muscle by activation of inhibitor kappaB kinase in a p38 MAPK-dependent manner. J Biol Chem. 2004;279(17):17070–8.PubMedCrossRefGoogle Scholar
  106. De Jesus DF, Kulkarni RN. Epigenetic modifiers of islet function and mass. Trends Endocrinol Metab. 2014;25(12):628–36.PubMedCrossRefGoogle Scholar
  107. Deeb SS, Fajas L, Nemoto M, et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet. 1998;20(3):284–7.PubMedCrossRefGoogle Scholar
  108. DeFronzo RA. Glucose intolerance and aging: evidence for tissue insensitivity to insulin. Diabetes. 1979;28(12):1095–101.PubMedCrossRefGoogle Scholar
  109. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus: metabolic and molecular implications for identifying diabetes genes. Diabetes. 1997;5:117–269.Google Scholar
  110. DeFronzo RA. Lilly lecture. The triumvirate: beta cell, muscle, liver. A collusion responsible for NIDDM. Diabetes. 1998;37:667–87.CrossRefGoogle Scholar
  111. DeFronzo RA. Dysfunctional fat cells, lipotoxicity, and type 2 diabetes. Int J Clin Pract. 2004;143(Suppl):9–21.CrossRefGoogle Scholar
  112. DeFronzo RA. Is insulin resistance atherogenic? Possible mechanisms. Atheroscler Suppl. 2006;7:11–5.PubMedCrossRefGoogle Scholar
  113. DeFronzo RA. Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773–95.PubMedPubMedCentralCrossRefGoogle Scholar
  114. DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard lecture 2009. Diabetologia. 2010;53:1270–87.PubMedPubMedCentralCrossRefGoogle Scholar
  115. DeFronzo RA, Abdul-Ghani MA. Preservation of beta-cell function: the key to diabetes prevention. J Clin Endocrinol Metab. 2011;96(8):2354–66.PubMedCrossRefGoogle Scholar
  116. DeFronzo RA, Ferrannini E. Regulation of hepatic glucose metabolism in humans. Diabetes Metab Rev. 1987;3:415–60.PubMedCrossRefGoogle Scholar
  117. DeFronzo RA, Ferrannini E. Regulation of intermediatory metabolism during fasting and feeding. In: Jameson JL, DeGroot LJ, editors. Endocrinology. Philadelphia: Saunders Elsevier; 2010. p. 673–98.Google Scholar
  118. DeFronzo RA, Ferrannini E, Hendler R, et al. Influence of hyperinsulinemia, hyperglycemia, and the route of glucose administration on splanchnic glucose exchange. PNAS. 1978a;75:5173–7.PubMedCrossRefGoogle Scholar
  119. DeFronzo RA, Soman V, Sherwin RS, et al. Insulin binding to monocytes and insulin action in human obesity, starvation, and refeeding. J Clin Investig. 1978b;62:204–13.PubMedCrossRefGoogle Scholar
  120. DeFronzo RA, Ferrannini E, Wahren J, Felig P. Lack of gastrointestinal mediator of insulin action in maturity onset diabetes. Lancet. 1978c;2:1077–9.PubMedCrossRefPubMedCentralGoogle Scholar
  121. DeFronzo RA, Diebert D, Hendler R, Felig P. Insulin sensitivity and insulin binding in maturity onset diabetes. J Clin Investig. 1979a;63:939–46.PubMedCrossRefPubMedCentralGoogle Scholar
  122. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979b;6:E214–23.Google Scholar
  123. DeFronzo RA, Jacot E, Jequier E, et al. The effect of insulin on the disposal of intravenous glucose: results from indirect calorimetry. Diabetes. 1981;30:1000–7.PubMedCrossRefPubMedCentralGoogle Scholar
  124. DeFronzo RA, Ferrannini E, Hendler R, et al. Regulation of splanchnic and peripheral glucose uptake by insulin and hyperglycemia. Diabetes. 1983;32:35–45.PubMedPubMedCentralCrossRefGoogle Scholar
  125. DeFronzo RA, Gunnarsson R, Bjorkman O, et al. Effects of insulin on peripheral and splanchnic glucose metabolism in non-insulin dependent diabetes mellitus. J Clin Investig. 1985;76:149–55.PubMedCrossRefPubMedCentralGoogle Scholar
  126. DeFronzo RA, Ferrannini E, Simonson DC. Fasting hyperglycemia in non-insulin dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism. 1989;38:387–95.PubMedCrossRefPubMedCentralGoogle Scholar
  127. DeFronzo RA, Tripathy D, Schwenke DC, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011;364:1104–15.PubMedCrossRefGoogle Scholar
  128. DeFronzo RA, Tripathy D, Schwenke DC, et al. Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlates. Diabetes. 2013a;62(11):3920–6.PubMedPubMedCentralCrossRefGoogle Scholar
  129. DeFronzo RA, Hompesch M, Kasichayanula S, et al. Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. Diabetes Care. 2013b;36(10):3169–76.PubMedPubMedCentralCrossRefGoogle Scholar
  130. DeFronzo RA, Tripathy D, Abdul-Ghani M, Musi N, Gastaldelli A. The disposition index does not reflect beta-cell function in IGT subjects treated with pioglitazone. J Clin Endocrinol Metab. 2014;99(10):3774–81.PubMedCrossRefPubMedCentralGoogle Scholar
  131. DeFronzo RA, Ferrannini E, Groop L, et al. Type 2 diabetes mellitus. Nat Rev Dis Primers. 2015;1:15019.PubMedCrossRefGoogle Scholar
  132. DeFronzo RA, Norton L, Abdul-Ghani M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol. 2017;13:11–26.PubMedCrossRefGoogle Scholar
  133. Degn KB, Juhl CB, Sturis J, et al. One week’s treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes. 2004;53:1187–94.PubMedCrossRefGoogle Scholar
  134. Del Guerra S, Lupi R, Marselli L, et al. Functional and molecular defects of pancreatic islets in human type 2 diabetes. Diabetes. 2005;54(3):727–35.PubMedCrossRefGoogle Scholar
  135. Del Prato S, Bonadonna RC, Bonora E, et al. Characterization of cellular defects of insulin action in type 2 (non-insulin-dependent) diabetes mellitus. J Clin Investig. 1993;91:484–94.PubMedCrossRefGoogle Scholar
  136. Del Prato S, Simonson DC, Sheehan P, et al. Studies on the mass effect of glucose in diabetes. Evidence for glucose resistance. Diabetologia. 1997;40:687–97.PubMedCrossRefGoogle Scholar
  137. Dent P, Lavoinne A, Nakielny S, et al. The molecular mechanisms by which insulin stimulates glycogen synthesis in mammalian skeletal muscle. Nature. 1990;348:302–7.PubMedCrossRefGoogle Scholar
  138. Desgraz R, Bonal C, Herrera PL. beta-cell regeneration: the pancreatic intrinsic faculty. Trends Endocrinol Metab. 2011;22(1):34–43.PubMedCrossRefGoogle Scholar
  139. Despres JP, Moorjani S, Lupien PJ, Tremblay A, Nadeau A, Bouchard C. Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Arteriosclerosis. 1990;10(4):497–511.PubMedCrossRefGoogle Scholar
  140. Diabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University, Novartis Institutes of BioMedical Research, et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science. 2007;316(5829):1331–6.CrossRefGoogle Scholar
  141. Diamond MP, Thornton K, Connolly-Diamond M, et al. Reciprocal variation in insulin-stimulated glucose uptake and pancreatic insulin secretion in women with normal glucose tolerance. J Soc Gynecol Investig. 1995;2:708–15.PubMedCrossRefGoogle Scholar
  142. Dominguez JH, Camp K, Maianu L, et al. Molecular adaptations of GLUT1 and GLUT2 in renal proximal tubules of diabetic rats. Am J Physiol. 1994;266:F283–90.PubMedGoogle Scholar
  143. Dowse GK, Zimmet PZ, Collins VR. Insulin levels and the natural history of glucose intolerance in Nauruans. Diabetes. 1996;45:1367–72.PubMedCrossRefGoogle Scholar
  144. Draznin B. Molecular mechanisms of insulin resistance: serine phosphorylation of insulin receptor substrate-1 and increased expression of p85alpha: the two sides of a coin. Diabetes. 2006;55:2392–7.PubMedPubMedCentralCrossRefGoogle Scholar
  145. Dresner A, Laurent D, Marcucci M, et al. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest. 1999;103(2):253–9.PubMedPubMedCentralCrossRefGoogle Scholar
  146. Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3:153–65.PubMedCrossRefGoogle Scholar
  147. Drucker DJ. Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls. Diabetes. 2013;62(10):3316–23.PubMedPubMedCentralCrossRefGoogle Scholar
  148. Ducluzeau P-H, Perretti N, Laville M, et al. Regulation by insulin of gene expression in human skeletal muscle and adipose tissue. Evidence for specific defects in type 2 diabetes. Diabetes. 2001;50:1134–42.PubMedCrossRefGoogle Scholar
  149. Echwald SM, Bjorbaek C, Hansen T, et al. Identification of four amino acid substitutions in hexokinase II and studies of relationships to NIDDM, glucose effectiveness, and insulin sensitivity. Diabetes. 1995;44:347–53.PubMedCrossRefGoogle Scholar
  150. Edgerton DS, Cherrington AD. Is brain insulin action relevant to the control of plasma glucose in humans? Diabetes Educ. 2015;64:696–9.CrossRefGoogle Scholar
  151. Efendic S, Grill V, Luft R, Wajngot A. Low insulin response: a marker of pre-diabetes. Adv Exp Med Biol. 1988;246:167–74.PubMedCrossRefGoogle Scholar
  152. Eizirik DL, Cardozo AK, Cnop M. The role for endoplasmic reticulum stress in diabetes mellitus. Endocr Rev. 2008;29(1):42–61.PubMedCrossRefGoogle Scholar
  153. Ekberg K, Landau BR, Wajngot A, et al. Contributions by kidney and liver to glucose production in the postabsorptive state and after 60 h of fasting. Diabetes. 1999;48:292–8.PubMedCrossRefGoogle Scholar
  154. Elbein SC, Hoffman M, Qin H, et al. Molecular screening of the glucokinase gene in familial type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1994;37:182–7.PubMedCrossRefGoogle Scholar
  155. Ellis BA, Poynten A, Lowy AJ, et al. Long-chain acyl-CoA esters as indicators of lipid metabolism and insulin sensitivity in rat and human muscle. Am J Physiol Endocrinol Metab. 2000;279:E554–60.PubMedCrossRefGoogle Scholar
  156. Eriksson UJ. Lifelong consequences of metabolic adaptations in utero? Diabetologia. 1996;39:1123–5.PubMedCrossRefGoogle Scholar
  157. Eriksson J, Franssila-Kallunki A, Ekstrand A, et al. Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. N Engl J Med. 1989;321:337–43.PubMedCrossRefGoogle Scholar
  158. Eriksson J, Koranyi L, Bourey R, et al. Insulin resistance in type 2 (non-insulin-dependent) diabetic patients and their relatives is not associated with a defect in the expression of the insulin-responsive glucose transporter (GLUT-4) gene in human skeletal muscle. Diabetologia. 1992;35:143–7.PubMedCrossRefGoogle Scholar
  159. Fabbrini E, Tamboli RA, Magkos F, et al. Surgical removal of omental fat does not improve insulin sensitivity and cardiovascular risk factors in obese adults. Gastroenterology. 2010;139(2):448–55.PubMedPubMedCentralCrossRefGoogle Scholar
  160. Falholt K, Jensen I, Lindkaer Jensen S, et al. Carbohydrate and lipid metabolism of skeletal muscle in type 2 diabetic patients. Diabet Med. 1988;5:27–31.PubMedCrossRefGoogle Scholar
  161. Farber SJ, Berger EY, Earle DP. Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose. J Clin Investig. 1951;30:125–9.PubMedCrossRefGoogle Scholar
  162. Ferrannini E, DeFronzo RA. Insulin actions in vivo: glucose metabolism. In: Zimmet P, Alberti KGMM, editors. International textbook of diabetes mellitus. Chichester: Wiley; 2015. p. 211–33.CrossRefGoogle Scholar
  163. Ferrannini E, Mari A. Beta cell function and its relation to insulin action in humans: a critical appraisal. Diabetologia. 2004;47(5):943–56.PubMedPubMedCentralCrossRefGoogle Scholar
  164. Ferrannini E, Mari A. beta-Cell function in type 2 diabetes. Metabolism. 2014;63(10):1217–27.PubMedPubMedCentralCrossRefGoogle Scholar
  165. Ferrannini E, Mingrone G. Impact of different bariatric surgical procedures on insulin action and beta-cell function in type 2 diabetes. Diabetes Care. 2009;32(3):514–20.PubMedPubMedCentralCrossRefGoogle Scholar
  166. Ferrannini E, Wahren J, Felig P, DeFronzo RA. Role of fractional glucose extraction in the regulation of splanchnic glucose metabolism in normal and diabetic man. Metabolism. 1980;29:28–35.PubMedCrossRefGoogle Scholar
  167. Ferrannini E, Barrett EJ, Bevilacqua S, DeFronzo RA. Effect of fatty acids on glucose production and utilization in man. J Clin Invest. 1983;72(5):1737–47.PubMedPubMedCentralCrossRefGoogle Scholar
  168. Ferrannini E, Bjorkman O, Reichard GA Jr, et al. The disposal of an oral glucose load in healthy subjects. A quantitative study. Diabetes. 1985;34:580–8.PubMedCrossRefGoogle Scholar
  169. Ferrannini E, Simonson DC, Katz LD, et al. The disposal of an oral glucose load in patients with non-insulin dependent diabetes. Metabolism. 1988;37:79–85.PubMedCrossRefGoogle Scholar
  170. Ferrannini E, Natali A, Bell P, et al. Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). J Clin Investig. 1997;100:1166–73.PubMedCrossRefGoogle Scholar
  171. Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J Clin Endocrinol Metab. 2005;90(1):493–500.PubMedCrossRefGoogle Scholar
  172. Ferrannini E, Natali A, Muscelli E, et al. Natural history and physiological determinants of changes in glucose tolerance in a non-diabetic population: the RISC study. Diabetologia. 2011;54:1507–16.PubMedCrossRefGoogle Scholar
  173. Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014;124(2):499–508.PubMedPubMedCentralCrossRefGoogle Scholar
  174. Feuerer M, Herrero L, Cipolletta D, et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med. 2009;15(8):930–9.PubMedPubMedCentralCrossRefGoogle Scholar
  175. Firth R, Bell P, Rizza R. Insulin action in non-insulin-dependent diabetes mellitus: the relationship between hepatic and extrahepatic insulin resistance and obesity. Metabolism. 1987;36:1091–5.PubMedCrossRefGoogle Scholar
  176. Flannick J, Thorleifsson G, Beer NL, et al. Loss-of-function mutations in SLC30A8 protect against type 2 diabetes. Nat Genet. 2014;46(4):357–63.PubMedPubMedCentralCrossRefGoogle Scholar
  177. Flier JS, Minaker KL, Landsberg L, Young JB, Pallotta J, Rowe JW. Impaired in vivo insulin clearance in patients with severe target-cell resistance to insulin. Diabetes. 1982;31(2):132–5.PubMedCrossRefGoogle Scholar
  178. Folli F, Saad JA, Backer JM, Kahn CR. Regulation of phosphatidylinositol 3-kinase activity in liver and muscle of animal models of insulin-resistant and insulin-deficient diabetes mellitus. J Clin Investig. 1993;92:1787–94.PubMedCrossRefGoogle Scholar
  179. Forslund K, Hildebrand F, Nielsen T, et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature. 2015;528(7581):262–6.PubMedPubMedCentralCrossRefGoogle Scholar
  180. Frame S, Cohen P. GSK3 takes centre stage more than 20 years after its discovery. Biochem J. 2001;359(Pt 1):1–16.PubMedPubMedCentralCrossRefGoogle Scholar
  181. Frayn KN. Visceral fat and insulin resistance--causative or correlative? Br J Nutr. 2000;83(Suppl 1):S71–7.PubMedGoogle Scholar
  182. Freidenberg GR, Henry RR, Klein HH, et al. Decreased kinase activity of insulin receptors from adipocytes of non-insulin-dependent diabetic studies. J Clin Investig. 1987;79:240–50.PubMedCrossRefGoogle Scholar
  183. Freidenberg GR, Reichart D, Olefsky JM, Henry RR. Reversibility of defective adipocyte insulin receptor kinase activity in non-insulin dependent diabetes mellitus. Effect of weight loss. J Clin Investig. 1988;82:1398–406.PubMedCrossRefGoogle Scholar
  184. Fuchsberger C, Flannick J, Teslovich TM, et al. The genetic architecture of type 2 diabetes. Nature. 2016;536(7614):41–7.PubMedPubMedCentralCrossRefGoogle Scholar
  185. Gaggini M, Morelli M, Buzzigoli E, DeFronzo RA, Bugianesi E, Gastaldelli A. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Forum Nutr. 2013;5(5):1544–60.Google Scholar
  186. Garvey WT. Insulin action and insulin resistance: diseases involving defects in insulin receptors, signal transduction, and the glucose transport effector system. Am J Med. 1998;105:331–45.PubMedCrossRefGoogle Scholar
  187. Garvey WT, Olefsky JM, Griffin J, et al. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes. 1985;34:222–34.PubMedCrossRefGoogle Scholar
  188. Garvey WT, Huecksteadt TP, Mattaei S, Olefsky JM. Role of glucose transporters in the cellular insulin resistance of type II non-insulin dependent diabetes mellitus. J Clin Investig. 1988;81:1528–36.PubMedCrossRefGoogle Scholar
  189. Gastaldelli A, Baldi S, Pettiti M, et al. Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study. Diabetes. 2000;49:1367–73.PubMedPubMedCentralCrossRefGoogle Scholar
  190. Gastaldelli A, Ferrannini E, Miyazaki Y, et al. Beta cell dysfunction and glucose intolerance: results from the San Antonio Metabolism (SAM) study. Diabetologia. 2004;47:31–9.PubMedPubMedCentralCrossRefGoogle Scholar
  191. Gastaldelli A, Miyazaki Y, Mahankali A, et al. The effect of pioglitazone on the liver: role of adiponectin. Diabetes Care. 2006;29(10):2275–81.PubMedCrossRefGoogle Scholar
  192. Gastaldelli A, Ferrannini E, Miyazaki Y, et al. Thiazolidinediones improve beta-cell function in type 2 diabetic patients. Am J Physiol Endocrinol Metab. 2007a;292:E871–83.PubMedCrossRefGoogle Scholar
  193. Gastaldelli A, Cusi K, Pettiti M, et al. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology. 2007b;133(2):496–506.PubMedCrossRefGoogle Scholar
  194. Gautier JF, Wilson C, Weyer C, et al. Low acute insulin secretory responses in adult offspring of people with early onset type 2 diabetes. Diabetes. 2001;50:1828–33.PubMedCrossRefGoogle Scholar
  195. Gerich JE, Meyer C, Woerle HJ, Stumvoll M. Renal gluconeogenesis: its importance in human glucose homeostasis. Diabetes Care. 2001;24(2):382–91.10.PubMedCrossRefGoogle Scholar
  196. Gianani R. Beta cell regeneration in human pancreas. Semin Immunopathol. 2011;33(1):23–7.CrossRefGoogle Scholar
  197. Ginsberg H, Kimmerling G, Olefsky JM, Reaven GM. Demonstration of insulin resistance in untreated adult-onset diabetic subjects with fasting hyperglycemia. J Clin Investig. 1975;55:454–61.PubMedCrossRefGoogle Scholar
  198. Godfrey KM, Reynolds RM, Prescott SL, et al. Influence of maternal obesity on the long-term health of offspring. Lancet Diabetes Endocrinol. 2017;5(1):53–64.PubMedCrossRefGoogle Scholar
  199. Golay A, DeFronzo RA, Ferrannini E, et al. Oxidative and non-oxidative glucose metabolism in non-obese type 2 (non-insulin dependent) diabetic patients. Diabetologia. 1988;31:585–91.PubMedCrossRefGoogle Scholar
  200. Goldfine AB, Kulkarni RN. Modulation of β-cell function: a translational journal from the bench to the bedside. Diabetes Obes Metab. 2012;14(Suppl 3):152–60.PubMedCrossRefGoogle Scholar
  201. Goldfine AB, Fonseca V, Jablonski KA, et al. The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann Intern Med. 2010;152(6):346–57.PubMedPubMedCentralCrossRefGoogle Scholar
  202. Grant SF, Thorleifsson G, Reynisdottir I, et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet. 2006;38:320–3.PubMedCrossRefGoogle Scholar
  203. Gregg EW, Chen H, Wagenknecht LE, et al. Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA. 2012;308(23):2489–96.PubMedPubMedCentralCrossRefGoogle Scholar
  204. Griffin ME, Marcucci MJ, Cline GW, et al. Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade. Diabetes. 1999;48:1270–4.PubMedCrossRefGoogle Scholar
  205. Grill V. A comparison of brain glucose metabolism in diabetes as measured by positron emission tomography or by arteriovenous techniques. Ann Med. 1990;22:171–5.PubMedCrossRefGoogle Scholar
  206. Groop L, Lyssenko V. Genes and type 2 diabetes mellitus. Curr Diab Rep. 2008;8:192–7.PubMedCrossRefGoogle Scholar
  207. Groop LC, Bonadonna RC, Del Prato S, et al. Glucose and free fatty acid metabolism in non-insulin dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. J Clin Investig. 1989;84:205–15.PubMedCrossRefGoogle Scholar
  208. Groop LC, Saloranta C, Shank M, Bonadonna RC, Ferrannini E, DeFronzo RA. The role of free fatty acid metabolism in the pathogenesis of insulin resistance in obesity and noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1991;72(1):96–107.PubMedCrossRefGoogle Scholar
  209. Groop L, Bonadonna R, Simonson DC, et al. Effect of insulin on oxidative and non-oxidative pathways of glucose and free fatty acid metabolism in human obesity. Am J Physiol. 1992;263:E79–84.PubMedGoogle Scholar
  210. Group DPPR. The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. Diabet Med. 2007;24:137–44.CrossRefGoogle Scholar
  211. Guardado-Mendoza R, Davalli AM, Chavez AO, et al. Pancreatic islet amyloidosis, beta-cell apoptosis, and alpha-cell proliferation are determinants of islet remodeling in type-2 diabetic baboons. PNAS. 2009;106:13992–7.PubMedCrossRefPubMedCentralGoogle Scholar
  212. Guilherme A, Virbasius JV, Puri V, Czech MP. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol. 2008;9(5):367–77.PubMedPubMedCentralCrossRefGoogle Scholar
  213. Gulli G, Ferrannini E, Stern M, et al. The metabolic profile of NIDDM is fully established in glucose-tolerant offspring of two Mexican-American NIDDM parents. Diabetes. 1992;41:1575–86.PubMedCrossRefPubMedCentralGoogle Scholar
  214. Gustavson SM, Chu CA, Nishizawa M, et al. Effects of hyperglycemia, glucagon, and epinephrine on renal glucose release in the conscious dog. Metabolism. 2004;53(7):933–41.PubMedCrossRefPubMedCentralGoogle Scholar
  215. Haataja L, Gurlo T, Huang CJ, Butler PC. Islet amyloid in type 2 diabetes and the toxic oligomer hypothesis. Endocr Rev. 2008;29:303–16.PubMedPubMedCentralCrossRefGoogle Scholar
  216. Haffner SM, Miettinen H, Gaskill SP, Stern MP. Decreased insulin secretion and increased insulin resistance are independently related to the 7-year risk of NIDDM in Mexican-Americans. Diabetes. 1995;44:1386–91.PubMedCrossRefPubMedCentralGoogle Scholar
  217. Halban PA, German MS, Kahn SE, Weir GC. Current status of islet cell replacement and regeneration therapy. J Clin Endocrinol Metab. 2010;95(3):1034–43.PubMedPubMedCentralCrossRefGoogle Scholar
  218. Hanley AJ, Williams K, Stern MP, Haffner SM. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio heart study. Diabetes Care. 2002;25:1177–84.CrossRefGoogle Scholar
  219. Hanley SC, Austin E, Assouline-Thomas B, et al. {beta}-Cell mass dynamics and islet cell plasticity in human type 2 diabetes. Endocrinology. 2010;151(4):1462–72.PubMedCrossRefPubMedCentralGoogle Scholar
  220. Hansen BC, Bodkin NH. Heterogeneity of insulin responses: phases leading to type 2 (noninsulin-dependent) diabetes mellitus in the rhesus monkey. Diabetologia. 1986;29:713–9.PubMedCrossRefGoogle Scholar
  221. Haus JM, Kashyap SR, Kasumov T, et al. Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance. Diabetes. 2009;58(2):337–43.PubMedPubMedCentralCrossRefGoogle Scholar
  222. Hedley AA, Ogden CL, Johnson CL, et al. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999–2002. JAMA. 2004;291:2847–50.PubMedCrossRefGoogle Scholar
  223. Helgason A, Palsson S, Thorleifsson G, et al. Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution. Nat Genet. 2007;39:218–25.PubMedCrossRefGoogle Scholar
  224. Henquin JC, Rahier J. Pancreatic alpha cell mass in European subjects with type 2 diabetes. Diabetologia. 2011;54(7):1720–5.PubMedPubMedCentralCrossRefGoogle Scholar
  225. Henry RR, Wallace P, Olefsky JM. Effects of weight loss on mechanisms of hyperglycemia in obese non-insulin-dependent diabetes mellitus. Diabetes. 1986;35:990–8.PubMedCrossRefGoogle Scholar
  226. Herschkovitz A, Liu YF, Ilan E, Ronen D, Boura-Halfon S, Zick Y. Common inhibitory serine sites phosphorylated by IRS-1 kinases, triggered by insulin and inducers of insulin resistance. J Biol Chem. 2007;282(25):18018–27.PubMedCrossRefGoogle Scholar
  227. Higa M, Zhou YT, Ravazzola M, et al. Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats. PNAS. 1999;96:11513–8.PubMedCrossRefGoogle Scholar
  228. Himsworth HP, Kerr RB. Insulin-sensitive and insulin-insensitive types of diabetes mellitus. Clin Sci. 1939;4:120–52.Google Scholar
  229. Hitman GA, Hawrammi K, McCarthy MI, et al. Insulin receptor substrate-1 gene mutations in NIDDM: implication for the study of polygenic disease. Diabetologia. 1995;38:481–6.PubMedPubMedCentralCrossRefGoogle Scholar
  230. Hojberg PV, Vilsboll T, Rabol R, et al. Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia. 2009;52:199–207.PubMedCrossRefGoogle Scholar
  231. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87:1409–39.CrossRefPubMedGoogle Scholar
  232. Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab. 2004;287(2):E199–206.PubMedCrossRefGoogle Scholar
  233. Holst JJ, Knop FK, Vilsboll T, Krarup T, Madsbad S. Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes. Diabetes Care. 2011;34(Suppl 2):S251–7.PubMedPubMedCentralCrossRefGoogle Scholar
  234. Honka H, Makinen J, Hannukainen JC, et al. Validation of [18F]fluorodeoxyglucose and positron emission tomography (PET) for the measurement of intestinal metabolism in pigs, and evidence of intestinal insulin resistance in patients with morbid obesity. Diabetologia. 2013;56(4):893–900.PubMedCrossRefGoogle Scholar
  235. Howard CF. Longitudinal studies on the development of diabetes in individual macaca nigra. Diabetologia. 1986;29:301–6.PubMedCrossRefGoogle Scholar
  236. Howard JK, Flier JS. Attenuation of leptin and insulin signaling by SOCS proteins. Trends Endocrinol Metab. 2006;17(9):365–71.PubMedCrossRefGoogle Scholar
  237. Howard G, Bergman R, Wagenknecht LE, et al. Ability of alternative indices of insulin sensitivity to predict cardiovascular risk: comparison with the “minimal model”. Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Ann Epidemiol. 1998;8:358–69.PubMedCrossRefGoogle Scholar
  238. Hsueh WA, Law RE. Insulin signaling in the arterial wall. Am J Cardiol. 1999;84:21J–4J.PubMedCrossRefGoogle Scholar
  239. Hu Y, Li L, Xu Y, et al. Short-term intensive therapy in newly diagnosed type 2 diabetes partially restores both insulin sensitivity and beta-cell function in subjects with long-term remission. Diabetes Care. 2011;34(8):1848–53.PubMedPubMedCentralCrossRefGoogle Scholar
  240. Huang CJ, Lin CY, Haataja L, et al. High expression rates of human islet amyloid polypeptide induce endoplasmic reticulum stress mediated beta-cell apoptosis, a characteristic of humans with type 2 but not type 1 diabetes. Diabetes. 2007;56:2016–27.PubMedCrossRefGoogle Scholar
  241. Hundal RS, Petersen KF, Mayerson AB, et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Investig. 2002;109:1321–6.PubMedCrossRefPubMedCentralGoogle Scholar
  242. Igoillo-Esteve M, Marselli L, Cunha DA, et al. Palmitate induces a pro-inflammatory response in human pancreatic islets that mimics CCL2 expression by beta cells in type 2 diabetes. Diabetologia. 2010;53:1395–405.PubMedCrossRefPubMedCentralGoogle Scholar
  243. Imamura M, Maeda S. Genetics of type 2 diabetes: the GWAS era and future perspectives [Review]. Endocr J. 2011;58:723–39.PubMedCrossRefPubMedCentralGoogle Scholar
  244. Imamura T, Koffler M, Helderman JH, et al. Severe diabetes induced in subtotally depancreatized dogs by sustained hyperglycemia. Diabetes. 1988;37(5):600–9.PubMedCrossRefPubMedCentralGoogle Scholar
  245. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683–9.PubMedCrossRefPubMedCentralGoogle Scholar
  246. Itani SI, Ruderman NB, Schmieder F, Boden G. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaB-alpha. Diabetes. 2002;51:2005–11.CrossRefGoogle Scholar
  247. Jain R, Lammert E. Cell-cell interactions in the endocrine pancreas. Diabetes Obes Metab. 2009;11(Suppl 4):159–67.PubMedCrossRefPubMedCentralGoogle Scholar
  248. Jallut D, Golay A, Munger R, et al. Impaired glucose tolerance and diabetes in obesity: a 6 year follow-up study of glucose metabolism. Metabolism. 1990;39:1068–75.PubMedCrossRefPubMedCentralGoogle Scholar
  249. James WP. The fundamental drivers of the obesity epidemic. Obes Rev. 2008;9(Suppl 1):6–13.PubMedCrossRefPubMedCentralGoogle Scholar
  250. Jamison RA, Stark R, Dong J, et al. Hyperglucagonemia precedes a decline in insulin secretion and causes hyperglycemia in chronically glucose-infused rats. Am J Physiol Endocrinol Metab. 2011;301(6):E1174–83.PubMedPubMedCentralCrossRefGoogle Scholar
  251. Jastreboff AM, Sinha R, Lacadie C, et al. Neural correlates of stress- and food- cue-induced food craving in obesity: association with insulin levels. Diabetes Care. 2013;36(2):394–402.PubMedPubMedCentralCrossRefGoogle Scholar
  252. Jiang ZY, Lin YW, Clemont A, et al. Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. J Clin Investig. 1999;104:447–57.PubMedCrossRefGoogle Scholar
  253. Johnson AB, Argyraki M, Thow JC, Cooper BG, Fulcher G, Taylor R. Effect of increased free fatty acid supply on glucose metabolism and skeletal muscle glycogen synthase activity in normal man. Clin Sci (Lond). 1992;82(2):219–26.CrossRefGoogle Scholar
  254. Jones CN, Pei D, Staris P, Polonsky KS, Chen YD, Reaven GM. Alterations in the glucose-stimulated insulin secretory dose-response curve and in insulin clearance in nondiabetic insulin-resistant individuals. J Clin Endocrinol Metab. 1997;82(6):1834–8.PubMedCrossRefGoogle Scholar
  255. Joost H-G, Bell GI, Best JD, et al. Nomenclature of the GLUT/SLC2A family of sugar/polyol transport facilitators. Am J Physiol Endocrinol Metab. 2002;282:E974–6.PubMedCrossRefGoogle Scholar
  256. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia. 2003;46:3–19.PubMedCrossRefGoogle Scholar
  257. Kahn SE, Suvag S, Wright LA, Utzschneider KM. Interactions between genetic background, insulin resistance and β-cell function. Diabetes Obes Metab. 2012;14(Suppl 3):46–56.PubMedPubMedCentralCrossRefGoogle Scholar
  258. Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet. 2014;383(9922):1068–83.PubMedCrossRefGoogle Scholar
  259. Kamran M, Peterson RG, Dominguez JH. Overexpression of GLUT2 gene in renal proximal tubules of diabetic Zucker rats. J Am Soc Nephrol. 1997;8:943–8.PubMedGoogle Scholar
  260. Kanat M, Mari A, Norton L, et al. Distinct beta-cell defects in impaired fasting glucose and impaired glucose tolerance. Diabetes. 2012;61(2):447–53.PubMedPubMedCentralCrossRefGoogle Scholar
  261. Kanat M, DeFronzo RA, Abdul-Ghani MA. Treatment of prediabetes. World J Diabetes. 2015;6(12):1207–22.PubMedPubMedCentralCrossRefGoogle Scholar
  262. Kapitza C, Dahl K, Jacobsen JB, Axelsen MB, Flint A. The effects of semaglutide on β-cell function in subjects with type 2 diabetes. Diabetes. 2016;(Suppl 1):A262.Google Scholar
  263. Kashiwagi A, Verso MA, Andrews J, et al. In vitro insulin resistance of human adipocytes isolated from subjects with non-insulin-dependent diabetes mellitus. J Clin Investig. 1983;72:1246–54.PubMedCrossRefGoogle Scholar
  264. Kashyap SR, DeFronzo RA. The insulin resistance syndrome: physiological considerations. Diab Vasc Dis Res. 2007;4:13–9.PubMedCrossRefGoogle Scholar
  265. Kashyap S, Belfort R, Gastaldelli A, et al. A sustained increase in plasma free fatty acids impairs insulin secretion in non-diabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes. 2003;52:2461–74.PubMedCrossRefGoogle Scholar
  266. Kashyap SR, Roman LJ, McLain J, et al. Insulin resistance is associated with impaired nitric oxide synthase (NOS) activity in skeletal muscle of type 2 diabetic subjects. J Clin Endocrinol Metab. 2005;90:1100–5.PubMedCrossRefGoogle Scholar
  267. Katz H, Homan M, Jensen M, et al. Assessment of insulin action in NIDDM in the presence of dynamic changes in insulin and glucose concentration. Diabetes. 1994;43:289–96.PubMedCrossRefGoogle Scholar
  268. Kellerer M, Kroder G, Tippmer S, et al. Troglitazone prevents glucose-induced insulin resistance of insulin receptor in rat-1 fibroblasts. Diabetes. 1994;43:447–53.PubMedCrossRefGoogle Scholar
  269. Kelley D, Mandarino L. Fuel selection in human skeletal muscle in insulin resistance: a reexamination. Diabetes. 2000;49:677–83.PubMedCrossRefGoogle Scholar
  270. Kelley D, Mokan M, Mandarino L. Intracellular defects in glucose metabolism in obese patients with noninsulin-dependent diabetes mellitus. Diabetes. 1992;41:698–706.PubMedCrossRefGoogle Scholar
  271. Kerouz NJ, Horsch D, Pons S, Kahn CR. Differential regulation of insulin receptor substrates-1 and −2 (IRS-1 and IRS-2) and phosphatidylinositol 3-kinase isoforms in liver and muscle of the obese diabetic (ob/ob) mouse. J Clin Investig. 1997;100:3164–72.PubMedCrossRefGoogle Scholar
  272. Kim JK, Fillmore JJ, Chen Y, et al. Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc Natl Acad Sci U S A. 2001;98(13):7522–7.PubMedPubMedCentralCrossRefGoogle Scholar
  273. Kim YB, Ciaraldi TP, Kong A, et al. Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110 beta protein levels in skeletal muscle of type 2 diabetic subjects. Diabetes. 2002;51:443–8.PubMedCrossRefGoogle Scholar
  274. Klein HH, Vestergaard H, Kotzke G, Pedersen O. Elevation of serum insulin concentration during euglycemic hyperinsulinemic clamp studies leads to similar activation of insulin receptor kinase in skeletal muscle of subjects with and without NIDDM. Diabetes. 1995;344:1310–7.CrossRefGoogle Scholar
  275. Kleinridders A, Ferris HA, Cai W, Kahn CR. Insulin action in brain regulates systemic metabolism and brain function. Diabetes. 2014;63(7):2232–43.PubMedPubMedCentralCrossRefGoogle Scholar
  276. Knop FK, Vilsboll T, Hojberg PV, et al. Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? Diabetes. 2007;56:1951–9.PubMedCrossRefGoogle Scholar
  277. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403.CrossRefPubMedPubMedCentralGoogle Scholar
  278. Koivisto VA, DeFronzo RA. Physical training and insulin sensitivity. Diabetes Metab Rev. 1986;1:445–81.PubMedCrossRefGoogle Scholar
  279. Kolaczynski JW, Nyce MR, Considine RV, et al. Acute and chronic effects of insulin on leptin production in humans: studies in vivo and in vitro. Diabetes. 1996;45(5):699–701.PubMedCrossRefGoogle Scholar
  280. Kolterman OG, Gray RS, Griffin J, et al. Receptor and postreceptor defects contribute to the insulin resistance in noninsulin-dependent diabetes mellitus. J Clin Investig. 1981;68:957–69.PubMedCrossRefGoogle Scholar
  281. Kosaka K, Kuzuya T, Akanuma Y, Hagura R. Increase in insulin response after treatment of overt maturity onset diabetes mellitus is independent of the mode of treatment. Diabetologia. 1980;18:23–8.PubMedCrossRefGoogle Scholar
  282. Kotronen A, Seppala-Lindroos A, Bergholm R, Yki-Jarvinen H. Tissue specificity of insulin resistance in humans: fat in the liver rather than muscle is associated with features of the metabolic syndrome. Diabetologia. 2008;51(1):130–8.PubMedCrossRefGoogle Scholar
  283. Krook A, Bjornholm M, Galuska D, et al. Characterization of signal transduction and glucose transport in skeletal muscle from type 2 diabetic patients. Diabetes. 2000;49(2):284–92.PubMedCrossRefGoogle Scholar
  284. Krssak M, Falk Petersen K, Dresner A, et al. Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1H NMR spectroscopy study. Diabetologia. 1999;42(1):113–6.PubMedCrossRefGoogle Scholar
  285. Kulkarni RN, Bruning JC, Winnay JN, Postic C, Magnuson MA, Kahn CR. Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes. Cell. 1999;96(3):329–39.PubMedCrossRefGoogle Scholar
  286. Kullmann S, Heni M, Hallschmid M, Fritsche A, Preissl H, Haring HU. Brain insulin resistance at the crossroads of metabolic and cognitive disorders in humans. Physiol Rev. 2016;96(4):1169–209.PubMedCrossRefGoogle Scholar
  287. Kusari J, Verma US, Buse JB, et al. Analysis of the gene sequences of the insulin receptor and the insulin-sensitive glucose transporter (GLUT4) in patients with common-type non-insulin-dependent diabetes mellitus. J Clin Investig. 1991;88:1323–30.PubMedCrossRefGoogle Scholar
  288. Laakso M, Malkki M, Kekalainen P, et al. Polymorphisms of the human hexokinase II gene: lack of association with NIDDM and insulin resistance. Diabetologia. 1995;38:617–22.CrossRefGoogle Scholar
  289. Lapidus L, Bengtsson C, Larsson B, Pennert K, Rybo E, Sjostrom L. Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow up of participants in the population study of women in Gothenburg, Sweden. Br Med J (Clin Res Ed). 1984;289(6454):1257–61.CrossRefGoogle Scholar
  290. Lara-Castro C, Garvey WT. Intracellular lipid accumulation in liver and muscle and the insulin resistance syndrome. Endocrinol Metab Clin N Am. 2008;37(4):841–56.CrossRefGoogle Scholar
  291. Larsen PJ, Tennagels N. On ceramides, other sphingolipids and impaired glucose homeostasis. Mol Metab. 2014;3(3):252–60.PubMedPubMedCentralCrossRefGoogle Scholar
  292. Lazar DF, Wiese RJ, Brady MJ, et al. Mitogen-activated protein kinase kinase inhibition does not block the stimulation of glucose utilization by insulin. J Biol Chem. 1995;270:20801–7.PubMedCrossRefGoogle Scholar
  293. Leahy JL, Cooper HE, Weir GC. Impaired insulin secretion associated with near normoglycemia. Study in normal rats with 96-h in vivo glucose infusions. Diabetes. 1987;36:459–64.PubMedCrossRefGoogle Scholar
  294. Lebrun P, Van Obberghen E. SOCS proteins causing trouble in insulin action. Acta Physiol (Oxf). 2008;192(1):29–36.CrossRefGoogle Scholar
  295. Lee Y, Lingvay I, Szczepaniak LS, et al. Pancreatic steatosis: harbinger of type 2 diabetes in obese rodents. Int J Obes (Lond). 2010;34:396–400.CrossRefGoogle Scholar
  296. Lehto M, Huang X, Davis EM, et al. Human hexokinase II gene: exon-intron organization, mutation screening in NIDDM, and its relationship to muscle hexokinase activity. Diabetologia. 1995;38:1466–74.PubMedCrossRefGoogle Scholar
  297. Levy J, Atkinson AB, Bell PM, et al. Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast diet study. Diabet Med. 1998;15:290–6.PubMedCrossRefGoogle Scholar
  298. Li Y, Xu W, Liao Z, et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. Diabetes Care. 2004;27(11):2597–602.PubMedCrossRefGoogle Scholar
  299. Liang H, Tantiwong P, Shanmugasundaram K, et al. Effect of a sustained reduction in plasma free fatty acid concentration on insulin signaling and inflammation in skeletal muscle from human subjects. J Physiol. 2013;591(pt 11):2897–909.PubMedPubMedCentralCrossRefGoogle Scholar
  300. Lillioja A, Mott DM, Zawadzki JK, et al. Glucose storage is a major determinant of in vivo ‘insulin resistance’ in subjects with normal glucose tolerance. J Clin Endocrinol Metab. 1986;62:922–7.PubMedCrossRefGoogle Scholar
  301. Lillioja S, Nyomba BL, Saad MF, et al. Exaggerated early insulin release and insulin resistance in a diabetes-prone population: a metabolic comparison of Pima Indians and Caucasians. J Clin Endocrinol Metab. 1991;73:866–76.PubMedCrossRefGoogle Scholar
  302. Lillioja S, Mott DM, Spraul M, et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:1988–92.PubMedCrossRefGoogle Scholar
  303. Lim EL, Hollingsworth KG, Aribisala BS, et al. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia. 2011;54:2506–14.PubMedPubMedCentralCrossRefGoogle Scholar
  304. Lin CY, Gurlo T, Haataja L, et al. Activation of peroxisome proliferator-activated receptor-gamma by rosiglitazone protects human islet cells against human islet amyloid polypeptide toxicity by a phosphatidylinositol 3′-kinase-dependent pathway. J Clin Endocrinol Metab. 2005;90:6678–86.PubMedCrossRefGoogle Scholar
  305. Liu J, Wu X, Franklin JL, et al. Mammalian Tribbles homolog 3 impairs insulin action in skeletal muscle: role in glucose-induced insulin resistance. Am J Physiol Endocrinol Metab. 2010;298(3):E565–76.PubMedCrossRefGoogle Scholar
  306. Lonnroth P, Digirolamo M, Krotkiewski M, Smith U. Insulin binding and responsiveness in fat cells from patients with reduced glucose tolerance and type II diabetes. Diabetes. 1983;32:748–54.PubMedCrossRefGoogle Scholar
  307. Lumeng CN, Saltiel AR. Inflammatory links between obesity and metabolic disease. J Clin Invest. 2011;121(6):2111–7.PubMedPubMedCentralCrossRefGoogle Scholar
  308. Lupi R, Dotta F, Marselli L, et al. Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: evidence that beta-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated. Diabetes. 2002;51:1437–42.PubMedCrossRefGoogle Scholar
  309. Lupi R, Del Guerra S, Marselli L, et al. Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARgamma in the modulation of insulin secretion. Am J Physiol Endocrinol Metab. 2004;286:E560–7.PubMedCrossRefGoogle Scholar
  310. Luzi L, DeFronzo RA. Effect of loss of first-phase insulin secretion on hepatic glucose production and tissue glucose disposal in humans. Am J Phys. 1989;257(2 Pt 1):E241–6.Google Scholar
  311. Lyssenko V, Almgren P, Anevski D, et al. Botnia Study Group: predictors of and longitudinal changes in insulin sensitivity and secretion preceding onset of type 2 diabetes. Diabetes. 2005;54:166–74.PubMedCrossRefGoogle Scholar
  312. Lyssenko V, Lupi R, Marchetti P, et al. Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest. 2007;117(8):2155–63.PubMedPubMedCentralCrossRefGoogle Scholar
  313. Lyssenko V, Jonsson A, Almgren P, et al. Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med. 2008;359(21):2220–32.PubMedCrossRefGoogle Scholar
  314. Lyssenko V, Nagorny CL, Erdos MR, et al. Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion. Nat Genet. 2009;41(1):82–8.PubMedCrossRefGoogle Scholar
  315. Ma RC, Lin X, Jia W. Causes of type 2 diabetes in China. Lancet Diabetes Endocrinol. 2014;2(12):980–91.PubMedCrossRefGoogle Scholar
  316. Magnusson I, Rothman DL, Katz LD, et al. Increased rate of gluconeogenesis in type II diabetes mellitus. A 13C nuclear magnetic resonance study. J Clin Investig. 1992;90:1323–7.PubMedCrossRefGoogle Scholar
  317. Majer M, Mott DM, Mochizuki H, et al. Association of the glycogen synthase locus on 19q13 with NIDDM in Pima Indians. Diabetologia. 1996;39:314–21.PubMedCrossRefGoogle Scholar
  318. Mandarino LJ, Madar Z, Kolterman OG, et al. Adipocyte glycogen synthase and pyruvate dehydrogenase in obese and type II diabetic patients. Am J Physiol. 1986;251:E489–96.PubMedGoogle Scholar
  319. Mandarino LJ, Wright KS, Verity LS, et al. Effects of insulin infusion on human skeletal muscle pyruvate dehydrogenase, phosphofructokinase, and glycogen synthase. Evidence for their role in oxidative and nonoxidative glucose metabolism. J Clin Investig. 1987;80:655–63.PubMedCrossRefGoogle Scholar
  320. Mandarino LJ, Printz RL, Cusi KA, et al. Regulation of hexokinase II and glycogen synthase mRNA, protein, and activity in human muscle. Am J Physiol. 1995;269:E701–8.PubMedGoogle Scholar
  321. Mandarino LJ, Consoli A, Jain A, Kelley DE. Interaction of carbohydrate and fat fuels in human skeletal muscle: impact of obesity and NIDDM. Am J Physiol. 1996;270:E463–70.PubMedGoogle Scholar
  322. Mandarino L, Bonadonna R, McGuinness O, Wasserman D. Regulation of muscle glucose uptake in vivo. In: Jefferson LS, Cherrington AD, editors. Handbook of physiology. Section 7: The endocrine system. The endocrine pancreas and regulation of metabolism. vol. II. New York: Oxford University Press; 2001. p. 803–48.Google Scholar
  323. Marachett P, Ferrannini E. Beta cell mass and function in human type 2 diabetes. In: DeFronzo RA, Ferrannini E, Zimmet P, Alberto KGMM, editors. International textbook of diabetes mellitus. 4th ed. Chichester: Wiley; 2015. p. 413–25.Google Scholar
  324. Marchetti P, Lupi R, Federici M, et al. Insulin secretory function is impaired in isolated human islets carrying the Gly(972)-->Arg IRS-1 polymorphism. Diabetes. 2002;51:1419–24.PubMedCrossRefGoogle Scholar
  325. Marchetti P, Del Guerra S, Marselli L, et al. Pancreatic islets from type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by metformin. J Clin Endocrinol Metab. 2004;89(11):5535–41.PubMedCrossRefGoogle Scholar
  326. Mari A, Schmitz O, Gastaldelli A, Oestergaard T, Nyholm B, Ferrannini E. Meal and oral glucose tests for assessment of beta -cell function: modeling analysis in normal subjects. Am J Physiol Endocrinol Metab. 2002;283(6):E1159–66.PubMedCrossRefGoogle Scholar
  327. Marselli L, Suleiman M, Masini M, et al. Are we overestimating the loss of beta cells in type 2 diabetes? Diabetologia. 2014;57(2):362–5.PubMedCrossRefGoogle Scholar
  328. Martin BC, Warren JH, Krolewski AS, et al. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet. 1992;340:925–9.PubMedCrossRefGoogle Scholar
  329. Martin-Gronert MS, Ozanne SE. Metabolic programming of insulin action and secretion. Diabetes Obes Metab. 2012;14(Suppl 3):29–39.PubMedCrossRefGoogle Scholar
  330. Masini M, Bugliani M, Lupi R, et al. Autophagy in human type 2 diabetes pancreatic beta cells. Diabetologia. 2009;52(6):1083–6.PubMedCrossRefPubMedCentralGoogle Scholar
  331. Massillon D, Barzilai N, Hawkins M, Prus-Wertheimer D, Rossetti L. Induction of hepatic glucose-6-phosphatase gene expression by lipid infusion. Diabetes. 1997;46(1):153–7.PubMedCrossRefPubMedCentralGoogle Scholar
  332. Matchinsky FM. Banting lecture 1995. A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm. Diabetes. 1996;45:223–41.CrossRefGoogle Scholar
  333. Matsuda M, Liu Y, Mahankali S, et al. Altered hypothalamic function in response to glucose ingestion in obese humans. Diabetes. 1999;48:1801–6.PubMedCrossRefPubMedCentralGoogle Scholar
  334. Matsuda M, DeFronzo RA, Glass L, et al. Glucagon dose response curve for hepatic glucose production and glucose disposal in type 2 diabetic patients and normal individuals. Metabolism. 2002;51:1111–9.PubMedCrossRefPubMedCentralGoogle Scholar
  335. Matsui J, Terauchi Y, Kubota N, et al. Pioglitazone reduces islet triglyceride content and restores impaired glucose-stimulated insulin secretion in heterozygous peroxisome proliferator-activated receptor-gamma-deficient mice on a high-fat diet. Diabetes. 2004;53:2844–54.PubMedCrossRefPubMedCentralGoogle Scholar
  336. Mbanya J-CN, Pani LN, Mbanya DNS, et al. Reduced insulin secretion in offspring of African type 2 diabetic patients. Diabetes Care. 2000;23:1761–5.PubMedCrossRefPubMedCentralGoogle Scholar
  337. McCarthy MI, Froguel P. Genetic approaches to the molecular understanding of type 2 diabetes. Am J Physiol. 2002;283:E217–25.Google Scholar
  338. McClain DA, Lubas WA, Cooksey RC, et al. Altered glycan-dependent signaling induces insulin resistance and hyperleptinemia. Proc Natl Acad Sci U S A. 2002;99(16):10695–9.PubMedPubMedCentralCrossRefGoogle Scholar
  339. Meier JJ, Hucking K, Holst JJ, et al. Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes. Diabetes. 2001;50:2497–504.PubMedCrossRefPubMedCentralGoogle Scholar
  340. Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014;124(2):509–14.PubMedPubMedCentralCrossRefGoogle Scholar
  341. Merovci A, Mari A, Solis C, et al. Dapagliflozin lowers plasma glucose concentration and improves beta-cell function. J Clin Endocrinol Metab. 2015;100(5):1927–32.PubMedPubMedCentralCrossRefGoogle Scholar
  342. Merovci A, Abdul-Ghani M, Mari A, et al. Effect of dapagliflozin with and without acipimox on insulin sensitivity and insulin secretion in T2DM males. J Clin Endocrinol Metab. 2016;101(3):1249–56.PubMedPubMedCentralCrossRefGoogle Scholar
  343. Meyer C, Dostou J, Nadkarni V, Gerich J. Effects of physiological hyperinsulinemia on systemic, renal, and hepatic substrate metabolism. Am J Phys. 1998a;275(6 Pt 2):F915–21.Google Scholar
  344. Meyer C, Stumvoll M, Nadkarni V, et al. Abnormal renal and hepatic glucose metabolism in type 2 diabetes mellitus. J Clin Investig. 1998b;102:619–24.PubMedCrossRefGoogle Scholar
  345. Michaliszyn SF, Mari A, Lee S, et al. beta-Cell function, incretin effect, and incretin hormones in obese youth along the span of glucose tolerance from normal to prediabetes to type 2 diabetes. Diabetes. 2014;63(11):3846–55.PubMedPubMedCentralCrossRefGoogle Scholar
  346. Mitrakou A, Kelley D, Mokan M, et al. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med. 1992;326:22–9.PubMedCrossRefGoogle Scholar
  347. Miyazaki Y, He H, Mandarino LJ, DeFronzo RA. Rosiglitazone improves downstream insulin-receptor signaling in type 2 diabetic patients. Diabetes. 2003;52:1943–50.PubMedCrossRefGoogle Scholar
  348. Mogensen CE. Maximum tubular reabsorpiton capacity for glucose and renal hemodynamics during rapid hypertonic glucose infusion in normal and diabetic subjects. Scand J Clin Lab Investig. 1971;28:101–9.CrossRefGoogle Scholar
  349. Mogensen M, Sahlin K, Fernstrom M, et al. Mitochondrial respiration is decreased in skeletal muscle of patients with type 2 diabetes. Diabetes. 2007;56(6):1592–9.CrossRefPubMedGoogle Scholar
  350. Mohan V, Sharp PS, Aber VR, et al. Insulin resistance in maturity-onset diabetes of the young. Diabetes Metab. 1988;13:193–7.Google Scholar
  351. Moller DE, Yakota A, Flier JS. Normal insulin receptor cDNA sequence in Pima Indians with non-insulin-dependent diabetes mellitus. Diabetes. 1989;38:1496–500.PubMedCrossRefGoogle Scholar
  352. Moller N, Rizza RA, Ford GC, Nair KS. Assessment of postabsorptive renal glucose metabolism in humans with multiple glucose tracers. Diabetes. 2001;50:747–51.PubMedCrossRefGoogle Scholar
  353. Montagnani M, Chen H, Barr VA, Quon MJ. Insulin-stimulated activation of eNOS is independent of Ca2+ but requires phosphorylation by Akt at Ser(1179). J Biol Chem. 2001;276:30392–8.PubMedCrossRefGoogle Scholar
  354. Montane J, Kimek-Abercrombie A, Potter KJ, et al. Metabolic stress, IAPP and islet amyloid. Diabetes Obes Metab. 2012;14(Suppl 3):68–77.PubMedCrossRefGoogle Scholar
  355. Montell E, Turini M, Marotta M, et al. DAG accumulation from saturated fatty acids desensitizes insulin stimulation of glucose uptake in muscle cells. Am J Physiol Endocrinol Metab. 2001;280:E229–37.PubMedCrossRefGoogle Scholar
  356. Morino K, Petersen KF, Dufour S, et al. Reduced mitochondrial density and increased IRS-1 serine phosphorylation in muscle of insulin-resistant offspring of type 2 diabetic parents. J Clin Investig. 2005;115(12):3587–93.PubMedCrossRefGoogle Scholar
  357. Morris AP, Voight BF, Teslovich TM, et al. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet. 2012;44(9):981–90.PubMedPubMedCentralCrossRefGoogle Scholar
  358. Muller DC, Elahi D, Tobin JD, Andres R. Insulin response during the oral glucose tolerance test: the role of age, sex, body fat and the pattern of fat distribution. Aging. 1996;8:13–21.PubMedGoogle Scholar
  359. Muscelli E, Mari A, Casolaro A, et al. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes. 2008;57(5):1340–8.PubMedCrossRefGoogle Scholar
  360. Musi N, Goodyear LJ. Insulin resistance and improvements in signal transduction. Endocrine. 2006;29:73–80.PubMedCrossRefGoogle Scholar
  361. Nagi DK, Pettitt DJ, Bennett PH, Klein R, Knowler WC. Diabetic retinopathy assessed by fundus photography in Pima Indians with impaired glucose tolerance and NIDDM. Diabet Med. 1997;14(6):449–56.PubMedCrossRefGoogle Scholar
  362. Nannipieri M, Mari A, Anselmino M, et al. The role of beta-cell function and insulin sensitivity in the remission of type 2 diabetes after gastric bypass surgery. J Clin Endocrinol Metab. 2011;96(9):E1372–9.PubMedCrossRefPubMedCentralGoogle Scholar
  363. Nauck MA, Meier JJ. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. Lancet Diabetes Endocrinol. 2016;4(6):525–36.PubMedCrossRefPubMedCentralGoogle Scholar
  364. Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986a;29(1):46–52.PubMedCrossRefPubMedCentralGoogle Scholar
  365. Nauck MA, Homberger E, Siegel EG, et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab. 1986b;63(2):492–8.PubMedCrossRefPubMedCentralGoogle Scholar
  366. Nauck MA, Vardarli I, Deacon CF, et al. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia. 2011;54:10–8.PubMedCrossRefPubMedCentralGoogle Scholar
  367. Newgard CB, Brady MJ, O’Doherty RB, Saltiel AR. Organizing glucose disposal. Emerging roles of the glycogen targeting subunits of protein phosphatase-1. Diabetes. 2000;49:1967–77.PubMedCrossRefPubMedCentralGoogle Scholar
  368. Nolan JJ, Friedenberg G, Henry R, et al. Role of human skeletal muscle insulin receptor kinase in the in vivo insulin resistance of noninsulin-dependent diabetes and obesity. J Clin Endocrinol Metab. 1994;78:471–7.PubMedPubMedCentralGoogle Scholar
  369. Noonan WT, Shaprio VM, Banks RO. Renal glucose reabsorption during hypertonic glucose infusion in female streptozotocin-induced diabetic rats. Life Sci. 2001;68:2967–77.PubMedCrossRefPubMedCentralGoogle Scholar
  370. Norton L, Shannon C, Fourcaudot M, Hu C, Wang N, Ren W, Song J, Abdul-Ghani M, DeFronzo RA, Ren J, Jia W. Sodium-glucose (SGLT) and glucose (GLUT) transporter expression in the kidney of type 2 diabetic subjects. Diabetes Obes Metab. 2017;19(9):1322–6.PubMedCrossRefPubMedCentralGoogle Scholar
  371. Nyomba BL, Freymond D, Raz I, et al. Skeletal muscle glycogen synthase activity in subjects with non-insulin-dependent diabetes mellitus after glyburide therapy. Metabolism. 1990;39:1204–10.PubMedCrossRefPubMedCentralGoogle Scholar
  372. Obici S, Feng Z, Tan J, et al. Central melanocortin receptors regulate insulin action. J Clin Investig. 2001;108:1079–85.PubMedCrossRefPubMedCentralGoogle Scholar
  373. Obici S, Feng Z, Karkanias G, et al. Decreasing hypothalamic insulin receptors causes hyperphagia and insulin resistance in rats. Nat Neurosci. 2002;5:566–72.PubMedCrossRefGoogle Scholar
  374. Ohsawa H, Kanatsuka A, Yamaguchi T, et al. Islet amyloid polypeptide inhibits glucose-stimulated insulin secretion from isolated rat pancreatic islets. Biochem Biophys Res Commun. 1989;160:961–7.PubMedCrossRefGoogle Scholar
  375. Olefsky JM, Reaven GM. Insulin binding in diabetes. Relationships with plasma insulin levels and insulin sensitivity. Diabetes. 1977;26:680–8.PubMedCrossRefGoogle Scholar
  376. Oliveira JM, Rebuffat SA, Gasa R, Gomis R. Targeting type 2 diabetes: lessons from a knockout model of insulin receptor substrate 2. Can J Physiol Pharmacol. 2014;92(8):613–20.PubMedCrossRefGoogle Scholar
  377. Orci L, Malaisse-Lagae F, Amherdt M, et al. Cell contacts in human islets of Langerhans. J Clin Endocrinol Metab. 1975;41(5):841–4.PubMedCrossRefGoogle Scholar
  378. Orho M, Nikua-Ijas P, Schalin-Jantti C, et al. Isolatation and characterization of the human muscle glycogen synthase gene. Diabetes. 1995;44:1099–105.PubMedCrossRefGoogle Scholar
  379. Osawa H, Sutherland C, Robey R, et al. Analysis of the signaling pathway involved in the regulation of hexokinase II gene transcription by insulin. J Biol Chem. 1996;271:16690–4.PubMedCrossRefGoogle Scholar
  380. Ozcan S. Minireview: microRNA function in pancreatic beta cells. Mol Endocrinol. 2014;28(12):1922–33.PubMedPubMedCentralCrossRefGoogle Scholar
  381. Ozcan U, Ozcan L, Yilmaz E, et al. Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis. Mol Cell. 2008;29(5):541–51.PubMedPubMedCentralCrossRefGoogle Scholar
  382. Pal D, Dasgupta S, Kundu R, et al. Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat Med. 2012;18(8):1279–85.CrossRefPubMedGoogle Scholar
  383. Park S, Choi SB. Induction of long-term normoglycemia without medication in Korean type 2 diabetes patients after continuous subcutaneous insulin infusion therapy. Diabetes Metab Res Rev. 2003;19(2):124–30.PubMedCrossRefGoogle Scholar
  384. Patane G, Anello M, Piro S, et al. Role of ATP production and uncoupling protein-2 in the insulin secretory defect induced by chronic exposure to high glucose or free fatty acids and effects of peroxisome proliferator-activated receptor-gamma inhibition. Diabetes. 2002;51:2749–56.PubMedCrossRefGoogle Scholar
  385. Patterson E, Ryan PM, Cryan JF, et al. Gut microbiota, obesity and diabetes. Postgrad Med J. 2016;92(1087):286–300.PubMedCrossRefGoogle Scholar
  386. Patti ME, Corvera S. The role of mitochondria in the pathogenesis of type 2 diabetes. Endocr Rev. 2010;31(3):364–95.PubMedPubMedCentralCrossRefGoogle Scholar
  387. Patti ME, Butte AJ, Crunkhorn S, et al. Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1. Proc Natl Acad Sci U S A. 2003;100(14):8466–71.PubMedPubMedCentralCrossRefGoogle Scholar
  388. Pedersen O, Bak J, Andersen P, et al. Evidence against altered expression of GLUT1 or GLUT4 in skeletal muscle of patients with obesity or NIDDM. Diabetes. 1990;39:865–70.PubMedCrossRefGoogle Scholar
  389. Pendergrass M, Koval J, Vogt C, et al. Insulin-induced hexokinase II expression is reduced in obesity and NIDDM. Diabetes. 1998a;47:387–94.PubMedCrossRefGoogle Scholar
  390. Pendergrass M, Nucci G, DeFronzo R. In vivo glucose transport (GT) and phosphorylation (GP) in skeletal muscle are impared by elevation of plasma FFA (Abstract). Diabetes. 1998b;47(Suppl 1):A65.Google Scholar
  391. Pendergrass M, Bertoldo A, Bonadonna R, et al. Muscle glucose transport and phosphorylation in type 2 diabetic, obese non-diabetic, and genetically predisposed individuals. Am J Physiol Endocrinol Metab. 2007;292:E92–100.PubMedCrossRefGoogle Scholar
  392. Perriott LM, Kono T, Whitesell RR, et al. Glucose uptake and metabolism by cultured human skeletal muscle cells: rate-limiting steps. Am J Physiol Endocrinol Metab. 2001;281:E72–80.PubMedCrossRefGoogle Scholar
  393. Petersen KF, Oral EA, Dufour S, et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest. 2002;109(10):1345–50.PubMedPubMedCentralCrossRefGoogle Scholar
  394. Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med. 2004;350(7):664–71.PubMedPubMedCentralCrossRefGoogle Scholar
  395. Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes. 2005;54(3):603–8.PubMedPubMedCentralCrossRefGoogle Scholar
  396. Phillips DIW. Insulin resistance as a programmed response to fetal undernutrition. Diabetologia. 1996;39:1119–22.PubMedCrossRefGoogle Scholar
  397. Plantinga LC, Crews DC, Coresh J, et al. Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes. Clin J Am Soc Nephrol. 2010;5(4):673–82.PubMedPubMedCentralCrossRefGoogle Scholar
  398. Plum L, Belgardt BF, Bruning JC. Central insulin action in energy and glucose homeostasis. J Clin Investig. 2006;116:1761–6.PubMedCrossRefGoogle Scholar
  399. Polonsky KS. Lilly lecture 1994. The beta cell in diabetes: from molecular genetics to clinical research. Diabetes. 1995;44:705–17.PubMedCrossRefGoogle Scholar
  400. Porte D. Central regulation of energy homeostasis. Diabetes. 2006;55(Suppl 2):S155–60.CrossRefGoogle Scholar
  401. Pratipanawatr W, Pratipanawatr T, Cusi K, et al. Skeletal muscle insulin resistance in normoglycemic subjects with a strong family history of type 2 diabetes is associated with decreased insulin-stimulated IRS-1 tyrosine phosphorylation. Diabetes. 2001;50:2572–8.PubMedCrossRefGoogle Scholar
  402. Pratipanawatr T, Cusi K, Ngo P, et al. Normalization of plasma glucose concentration by insulin therapy improves insulin-stimulated glycogen synthesis in type 2 diabetes. Diabetes. 2002;51:462–8.PubMedCrossRefGoogle Scholar
  403. Printz RL, Ardehali H, Koch S, Granner DK. Human hexokinase II mRNA and gene structure. Diabetes. 1995;44:290–4.PubMedCrossRefGoogle Scholar
  404. Procharzka M, Michizuki H, Baier LJ, et al. Molecular and linkage analysis of type-1 protein phosphatase catalytic beta-subunit gene: lack of evidence for its mjaor role in insulin resistance in Pima Indians. Diabetologia. 1995;38:461–6.CrossRefGoogle Scholar
  405. Qin J, Li Y, Cai Z, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490(7418):55–60.CrossRefPubMedGoogle Scholar
  406. Rahier J, Guiot Y, Goebbels RM, Sempoux C, Henquin JC. Pancreatic beta-cell mass in European subjects with type 2 diabetes. Diabetes Obes Metab. 2008;10(Suppl 4):32–42.PubMedCrossRefGoogle Scholar
  407. Rahmoune H, Thompson PW, Ward JM, et al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes. 2005;54:3427–34.PubMedCrossRefGoogle Scholar
  408. Rains JL, Jain SK. Oxidative stress, insulin signaling, and diabetes. Free Radic Biol Med. 2011;50(5):567–75.CrossRefPubMedGoogle Scholar
  409. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. 1963;1:785–9.PubMedPubMedCentralCrossRefGoogle Scholar
  410. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37:1595–607.PubMedCrossRefGoogle Scholar
  411. Reaven GM, Chen YD, Golay A, et al. Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1987;64:106–10.PubMedCrossRefGoogle Scholar
  412. Reaven GM, Hollenbeck CB, Chen YD. Relationship between glucose tolerance, insulin secretion, and insulin action in non-obese individuals with varying degrees of glucose tolerance. Diabetologia. 1989;32:52–5.PubMedCrossRefGoogle Scholar
  413. Reyna SM, Ghosh S, Tantiwong P, et al. Elevated toll-like receptor 4 expression and signaling in muscle from insulin-resistant subjects. Diabetes. 2008;57(10):2595–602.PubMedPubMedCentralCrossRefGoogle Scholar
  414. Richardson DK, Kashyap S, Bajaj M, et al. Lipid infusion induces an inflammatory/fibrotic response and decreases expression of nuclear encoded mitochondrial genes in human skeletal muscle. J Biol Chem. 2005;280:10290–7.PubMedCrossRefGoogle Scholar
  415. Ridaura VK, Faith JJ, Rey FE, et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science. 2013;341(6150):1241214.CrossRefGoogle Scholar
  416. Ritov VB, Menshikova EV, He J, Ferrell RE, Goodpaster BH, Kelley DE. Deficiency of subsarcolemmal mitochondria in obesity and type 2 diabetes. Diabetes. 2005;54(1):8–14.PubMedCrossRefGoogle Scholar
  417. Ritzel RA, Meier JJ, Lin CY, Veldhuis JD, Butler PC. Human islet amyloid polypeptide oligomers disrupt cell coupling, induce apoptosis, and impair insulin secretion in isolated human islets. Diabetes. 2007;56(1):65–71.PubMedCrossRefGoogle Scholar
  418. Roden M, Price TB, Perseghin G, et al. Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest. 1996;97(12):2859–65.PubMedPubMedCentralCrossRefGoogle Scholar
  419. Rogers PA, Fisher RA, Harris H. An electrophoretic study of the distribution and properties of human hexokinases. Biochem Genet. 1975;13:857–66.PubMedPubMedCentralCrossRefGoogle Scholar
  420. Romeo GR, Lee J, Shoelson SE. Metabolic syndrome, insulin resistance, and roles of inflammation--mechanisms and therapeutic targets. Arterioscler Thromb Vasc Biol. 2012;32(8):1771–6.PubMedPubMedCentralCrossRefGoogle Scholar
  421. Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol. 2007;8(7):519–29.PubMedCrossRefGoogle Scholar
  422. Rosengren AH, Jokubka R, Tojjar D, et al. Overexpression of alpha2A-adrenergic receptors contributes to type 2 diabetes. Science. 2010;327(5962):217–20.PubMedCrossRefGoogle Scholar
  423. Rosenthal M, Doberne L, Greenfield M, et al. Effect of age on glucose tolerance, insulin secretion, and in vivo insulin action. J Am Geriatr Soc. 1982;30:562–7.PubMedCrossRefGoogle Scholar
  424. Rossetti L, Shulman GI, Zawalich W, DeFronzo RA. Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. J Clin Investig. 1987a;80:1037–44.PubMedCrossRefGoogle Scholar
  425. Rossetti L, Smith D, Shulman GI, Papachristou D, DeFronzo RA. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest. 1987b;79(5):1510–5.PubMedPubMedCentralCrossRefGoogle Scholar
  426. Rossetti L, Giaccari A, DeFronzo RA. Glucose toxicity [Review]. Diabetes Care. 1990;13:610–30.PubMedCrossRefGoogle Scholar
  427. Rothman DL, Shulman RG, Shulman GI. 31P nuclear magnetic resonance measurements of muscle glucose-6-phosphate. Evidence for reduced insulin-dependent muscle glucose transport or phosphorylation activity in non-insulin-dependent diabetes mellitus. J Clin Investig. 1992;89:1069–75.PubMedCrossRefGoogle Scholar
  428. Rothman DL, Magnusson I, Cline G, et al. Decreased muscle glucose transport/phosphorylation is an early defect in the pathogenesis of non-insulin-dependent diabetes mellitus. PNAS. 1995;92:983–7.PubMedCrossRefGoogle Scholar
  429. Rutter MK, Meigs JB, Sullivan LM, et al. Insulin resistance, the metabolic syndrome, and incident cardiovascular events in the Framingham offspring study. Diabetes. 2005;54:3252–7.PubMedPubMedCentralCrossRefGoogle Scholar
  430. Saad MF, Knowler WC, Pettitt DJ, et al. The natural history of impaired glucose tolerance in the Pima Indians. N Engl J Med. 1988;319:1500–5.PubMedCrossRefGoogle Scholar
  431. Saad MF, Knowler WC, Pettitt DJ, et al. Sequential changes in serum insulin concentration during development of non-insulin-dependent diabetes. Lancet. 1989;1:1356–9.PubMedCrossRefGoogle Scholar
  432. Saad MF, Knowler WC, Pettitt DJ, Nelson RG, Charles MA, Bennett PH. A two-step model for development of non-insulin-dependent diabetes. Am J Med. 1991;90(2):229–35.PubMedCrossRefGoogle Scholar
  433. Sakuraba H, Mizukami H, Yagihashi N, et al. Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese type II diabetic patients. Diabetologia. 2002;45:85–96.PubMedCrossRefGoogle Scholar
  434. Salans LB, Bray GA, Cushman SW, et al. Glucose metabolism and the response to insulin by human adipose tissue in spontaneous and experimental obesity. Effects of dietary composition and adipose cell size. J Clin Investig. 1974;53:848–56.PubMedCrossRefGoogle Scholar
  435. Saltiel AR, Kahn CR. Insulin signaling and the regulation of glucose and lipid metabolism. Nature. 2001;414:799–806.PubMedPubMedCentralCrossRefGoogle Scholar
  436. Samuel VT, Shulman GI. The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. J Clin Invest. 2016;26:12–22.CrossRefGoogle Scholar
  437. Samuel VT, Liu ZX, Qu X, et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem. 2004;279(31):32345–53.PubMedCrossRefGoogle Scholar
  438. Samuel VT, Liu ZX, Wang A, et al. Inhibition of protein kinase C epsilon prevents hepatic insulin resistance in nonalcoholic fatty liver disease. J Clin Invest. 2007;117(3):739–45.PubMedPubMedCentralCrossRefGoogle Scholar
  439. Sandoval DA, D’Alessio DA. Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease. Physiol Rev. 2015;95(2):513–48.PubMedCrossRefGoogle Scholar
  440. Schalin-Jantti C, Harkoenen M, Groop LC. Impaired activation of glycogen synthase in people at increased risk for developing NIDDM. Diabetes. 1992;41:598–604.PubMedCrossRefGoogle Scholar
  441. Schwartz MW, Woods SC, Porte D, et al. Central nervous system control of food intake. Nature. 2000;404:661–71.CrossRefPubMedGoogle Scholar
  442. Seidell JC, Bouchard C. Visceral fat in relation to health: is it a major culprit or simply an innocent bystander? Int J Obes Relat Metab Disord. 1997;21(8):626–31.PubMedCrossRefGoogle Scholar
  443. Sengupta S, Peterson TR, Sabatini DM. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell. 2010;40(2):310–22.PubMedPubMedCentralCrossRefGoogle Scholar
  444. Shah OJ, Wang Z, Hunter T. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol. 2004;14(18):1650–6.PubMedCrossRefGoogle Scholar
  445. Sheperd PR, Nave BT, Siddle K. Insulin stimulation of glycogen synthesis and glycogen synthase activity is blocked by wortmannin and rapamycin in 3T3L1 adipocytes: evidence for the involvement of phosphoinositide 3 kinase and p70 ribosomal protein S6 kinase. Biochem J. 1995;305:25–8.CrossRefGoogle Scholar
  446. Shepherd PR, Kahn BB. Glucose transporters and insulin action. Implications for insulin resistance and diabetes mellitus. N Engl J Med. 1999;341:248–57.PubMedCrossRefGoogle Scholar
  447. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest. 2006;116(11):3015–25.PubMedPubMedCentralCrossRefGoogle Scholar
  448. Shulman GI, Rothman DL, Smith D, et al. Mechanism of liver glycogen repletion in vivo by nuclear magnetic resonance spectroscopy. J Clin Investig. 1985;76:1229–36.PubMedCrossRefGoogle Scholar
  449. Shulman GI, Rothman DL, Jue T, et al. Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy. N Engl J Med. 1990;322:223–8.PubMedCrossRefGoogle Scholar
  450. Sicree RA, Zimmet P, King HO, Coventry JO. Plasma insulin response among Nauruans. Prediction of deterioration in glucose tolerance over 6 years. Diabetes. 1987;36:179–86.PubMedCrossRefPubMedCentralGoogle Scholar
  451. Sigal RJ, Doria A, Warram JH, Krolewski AS. Codon 972 polymorphism in the insulin receptor substrate-1 gene, obesity, and risk of noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1996;81:1657–9.PubMedPubMedCentralGoogle Scholar
  452. Sladek R, Rocheleau G, Rung J, et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature. 2007;445(7130):881–5.PubMedCrossRefGoogle Scholar
  453. Sriwijitkamol A, Christ-Roberts C, Berria R, et al. Reduced skeletal muscle inhibitor of kappaB beta content is associated with insulin resistance in subjects with type 2 diabetes: reversal by exercise training. Diabetes. 2006;55(3):760–7.PubMedCrossRefPubMedCentralGoogle Scholar
  454. Starke A, Grundy S, McGarry JD, Unger RH. Correction of hyperglycemia with phloridzin restores the glucagon response to glucose in insulin-deficient dogs: implications for human diabetes. Proc Natl Acad Sci U S A. 1985;82(5):1544–6.PubMedPubMedCentralCrossRefGoogle Scholar
  455. Steck AK, Winter WE. Review on monogenic diabetes. Curr Opin Endocrinol Diabetes Obes. 2011;18:252–8.PubMedCrossRefPubMedCentralGoogle Scholar
  456. Stefan Y, Orci L, Malaisse-Lagae F, et al. Quantitation of endocrine cell content in the pancreas of nondiabetic and diabetic humans. Diabetes. 1982;31:694–700.PubMedCrossRefPubMedCentralGoogle Scholar
  457. Steinthorsdottir V, Thorleifsson G, Reynisdottir I, et al. A variant in CDKAL1 influences insulin response and risk of type 2 diabetes. Nat Genet. 2007;39:770–5.PubMedCrossRefGoogle Scholar
  458. Stumvoll M, Chintalapudi U, Perriello G, Welle S, Gutierrez O, Gerich J. Uptake and release of glucose by the human kidney. Postabsorptive rates and responses to epinephrine. J Clin Invest. 1995;96(5):2528–33.PubMedPubMedCentralCrossRefGoogle Scholar
  459. Stumvoll M, Meyer C, Kreider M, Perriello G, Gerich J. Effects of glucagon on renal and hepatic glutamine gluconeogenesis in normal postabsorptive humans. Metabolism. 1998;47(10):1227–32.PubMedCrossRefPubMedCentralGoogle Scholar
  460. Sugden MC, Holness MJ. Mechanisms underlying regulation of the expression and activities of the mammalian pyruvate dehydrogenase kinases. Arch Physiol Biochem. 2006;112(3):139–49.PubMedCrossRefPubMedCentralGoogle Scholar
  461. Sun XJ, Miralpeix M, Myers MG Jr, et al. Expression and function of IRS-1 in insulin signal transmission. J Biol Chem. 1992;267(31):22662–72.PubMedGoogle Scholar
  462. Szendroedi J, Yoshimura T, Phielix E, et al. Role of diacylglycerol activation of PKCtheta in lipid-induced muscle insulin resistance in humans. Proc Natl Acad Sci U S A. 2014;111(26):9597–602.PubMedPubMedCentralCrossRefGoogle Scholar
  463. Tang Y, Axelsson AS, Spegel P, et al. Genotype-based treatment of type 2 diabetes with an alpha2A-adrenergic receptor antagonist. Sci Transl Med. 2014;6(257):257ra139.PubMedCrossRefGoogle Scholar
  464. Tanijuchi CM, Emanuelli B, Kahn CR. Critical nodes in signaling pathways: insight into insulin action. Nat Rev Mol Cell Biol. 2006;7:85–96.CrossRefGoogle Scholar
  465. Tchernof A, Despres JP. Pathophysiology of human visceral obesity: an update. Physiol Rev. 2013;93(1):359–404.PubMedPubMedCentralCrossRefGoogle Scholar
  466. ten Kulve JS, Veltman DJ, van Bloemendaal L, et al. Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes. Diabetologia. 2015;58(12):2688–98.PubMedPubMedCentralCrossRefGoogle Scholar
  467. Teo AK, Gupta MK, Doria A, Kulkarni RN. Dissecting diabetes/metabolic disease mechanisms using pluripotent stem cells and genome editing tools. Mol Metab. 2015;4(9):593–604.PubMedPubMedCentralCrossRefGoogle Scholar
  468. Thiebaud D, Jacot E, DeFronzo RA, et al. The effect of graded doses of insulin on total glucose uptake, glucose oxidation, and glucose storage in man. Diabetes. 1982;31:957–63.PubMedCrossRefGoogle Scholar
  469. Thiebaud D, DeFronzo RA, Jacot E, et al. Effect of long chain triglyceride infusion on glucose metabolism in man. Metabolism. 1983;31:1128–36.CrossRefGoogle Scholar
  470. Thorburn AW, Gumbiner B, Bulacan F, et al. Intracellular glucose oxidation and glycogen synthase activity are reduced in non-insulin-dependent (type II) diabetes independent of impaired glucose uptake. J Clin Investig. 1990;85:522–9.PubMedCrossRefPubMedCentralGoogle Scholar
  471. Tiedge M, Lortz S, Drinkgern J, Lenzen S. Relation between antioxidant enzyme gene expression and antioxidative defense status of insulin-producing cells. Diabetes. 1997;46(11):1733–42.PubMedCrossRefGoogle Scholar
  472. Tilg H, Moschen AR. Microbiota and diabetes: an evolving relationship. Gut. 2014;63(9):1513–21.CrossRefPubMedGoogle Scholar
  473. Tordjman J, Khazen W, Antoine B, Chauvet G, Quette J, Fouque F, Beale EG, Benelli C, Forest C. Regulation of glyceroneogenesis and phosphoenolpyruvate carboxykinase by fatty acids, retinoic acids and thiazolidinediones: potential relevance to type 2 diabetes. Biochimie. 2004;85:1213–8.CrossRefGoogle Scholar
  474. Trayhurn P. Hypoxia and adipose tissue function and dysfunction in obesity. Physiol Rev. 2013;93(1):1–21.CrossRefPubMedGoogle Scholar
  475. Trichitta V, Brunetti A, Chiavetta A, et al. Defects in insulin-receptor internalization and processing in monocytes of obese subjects and obese NIDDM patients. Diabetes. 1989;38:1579–84.CrossRefGoogle Scholar
  476. Tura A, Muscelli E, Gastaldelli A, Ferrannini E, Mari A. Altered pattern of the incretin effect as assessed by modelling in individuals with glucose tolerance ranging from normal to diabetic. Diabetologia. 2014;57(6):1199–203.PubMedCrossRefGoogle Scholar
  477. Turer AT, Scherer PE. Adiponectin: mechanistic insights and clinical implications. Diabetologia. 2012;55(9):2319–26.PubMedCrossRefGoogle Scholar
  478. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444(7122):1027–31.PubMedPubMedCentralCrossRefGoogle Scholar
  479. Turpin SM, Nicholls HT, Willmes DM, et al. Obesity-induced CerS6-dependent C16:0 ceramide production promotes weight gain and glucose intolerance. Cell Metab. 2014;20(4):678–86.PubMedCrossRefGoogle Scholar
  480. Tushuizen ME, Bunck MC, Pouwels PJ, et al. Pancreatic fat content and beta-cell function in men with and without type 2 diabetes. Diabetes Care. 2007;30:2916–21.PubMedCrossRefGoogle Scholar
  481. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.CrossRefGoogle Scholar
  482. Unger RH, Aguilar-Parada E, Muller WA, Eisentraut AM. Studies of pancreatic alpha cell function in normal and diabetic subjects. J Clin Investig. 1970;49:837–48.PubMedCrossRefGoogle Scholar
  483. Vaag A, Henriksen JE, Beck-Nielsen H. Decreased insulin activation of glycogen synthase in skeletal muscles in young non-obese Caucasian first-degree relatives of patients with non-insulin-dependent diabetes mellitus. J Clin Investig. 1992;89:782–8.PubMedCrossRefPubMedCentralGoogle Scholar
  484. Vaag A, Henriksen JE, Madsbad S, et al. Insulin secretion, insulin action, and hepatic glucose production in identical twins discordant for non-insulin-dependent diabetes mellitus. J Clin Investig. 1995;95:690–8.PubMedCrossRefPubMedCentralGoogle Scholar
  485. Vague P, Moulin J-P. The defective glucose sensitivity of the B cell in insulin dependent diabetes. Improvement after twenty hours of normoglycaemia. Metabolism. 1982;31:139–42.PubMedCrossRefPubMedCentralGoogle Scholar
  486. van Bloemendaal L, RG IJ, Ten Kulve JS, et al. GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans. Diabetes. 2014;63(12):4186–96.PubMedCrossRefPubMedCentralGoogle Scholar
  487. Vauhkonen N, Niskanane L, Vanninen E, et al. Defects in insulin secretion and insulin action in non-insulin-dependent diabetes mellitus are inherited. Metabolic studies on offspring of diabetic probands. J Clin Investig. 1997;100:86–96.Google Scholar
  488. Vaxillaire M, Froguel P. Monogenic diabetes in the young, pharmacogenetics and relevance to multifactorial forms of type 2 diabetes. Endocr Rev. 2008;29:254–64.PubMedCrossRefPubMedCentralGoogle Scholar
  489. Vestergaard H, Bjocbaek C, Andersen PH, et al. Impaired expression of glycogen synthase mRNA in skeletal muscle of NIDDM patients. Diabetes. 1991;40:1740–5.PubMedCrossRefPubMedCentralGoogle Scholar
  490. Vestergaard H, Lund S, Larsen FS, et al. Glycogen synthase and phosphofructokinase protein and mRNA levels in skeletal muscle from insulin-resistant patients with non-insulin-dependent diabetes mellitus. J Clin Investig. 1993;91:2342–50.PubMedCrossRefPubMedCentralGoogle Scholar
  491. Vilsboll T, Krarup T, Madsbad S, Holst JJ. Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients. Diabetologia. 2002;45:1111–9.PubMedCrossRefPubMedCentralGoogle Scholar
  492. Virkamaki A, Ueki K, Kahn CR. Protein--protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. J Clin Investig. 1999;103:931–43.PubMedCrossRefPubMedCentralGoogle Scholar
  493. Vogt C, Ardehali H, Iozzo P, et al. Regulation of hexokinase II expression in human skeletal muscle in vivo. Metabolism. 2000;49:814–8.PubMedCrossRefPubMedCentralGoogle Scholar
  494. Wahren J, Felig P, Hagenfeldt L. Effect of protein ingestion on splanchnic and leg metabolism in normal man and in patients with diabetes mellitus. J Clin Investig. 1976;57:987–99.PubMedCrossRefGoogle Scholar
  495. Wang CC, Goalstone ML, Draznin B. Molecular mechanisms of insulin resistance that impact cardiovascular biology. Diabetes. 2004;53:2735–40.PubMedCrossRefGoogle Scholar
  496. Wang X, Misawa R, Zielinski MC, et al. Regional differences in islet distribution in the human pancreas--preferential beta-cell loss in the head region in patients with type 2 diabetes. PLoS One. 2013;8(6):e67454.PubMedPubMedCentralCrossRefGoogle Scholar
  497. Watanabe RM, Valle T, Hauser ER, et al. Familiarity of quantitative metabolic traits in Finnish families with non-insulin-dependent diabetes mellitus. Finland-United States Investigation of NIDDM Genes (FUSION) Study Investigators. Hum Hered. 1999;39:159–68.CrossRefGoogle Scholar
  498. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112(12):1796–808.PubMedPubMedCentralCrossRefGoogle Scholar
  499. Welters HJ, Kulkarni RN. Wnt signaling: relevance to β-cell biology and diabetes. Trends Endocrinol Metab. 2008;19:359–5.CrossRefGoogle Scholar
  500. Weng J, Li Y, Xu W, et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet. 2008;371:1753–60.PubMedCrossRefGoogle Scholar
  501. Westermark P, Wilander E. The influence of amyloid deposits on the islet volume in maturity onset diabetes mellitus. Diabetologia. 1978;15:417–21.PubMedCrossRefGoogle Scholar
  502. Westermark P, Andersson A, Westermark GT. Islet amyloid polypeptide, islet amyloid, and diabetes mellitus. Physiol Rev. 2011;91:795–826.PubMedCrossRefGoogle Scholar
  503. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest. 1999;104(6):787–94.PubMedPubMedCentralCrossRefGoogle Scholar
  504. Weyer C, Hanson RL, Tataranni PA, et al. A high fasting plasma insulin concentration predicts type 2 diabetes independent of insulin resistance. Evidence for a pathogenic role of relative hyperinsulinemia. Diabetes. 2000;49:2094–101.PubMedCrossRefGoogle Scholar
  505. Weyer C, Tataranni PA, Bogardus C, Pratley RE. Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care. 2001;24:89–94.PubMedCrossRefGoogle Scholar
  506. Williams KV, Price JC, Kelley DE. Interactions of impaired glucose transport and phosphorylation in skeletal muscle insulin resistance. A dose-response assessment using positron emission tomography. Diabetes. 2001;50:2069–79.PubMedCrossRefGoogle Scholar
  507. Williamson JR, Kreisberg RA, Felts PW. Mechanism for the stimulation of gluconeogenesis by fatty acids in perfused rat liver. Proc Natl Acad Sci U S A. 1966;56(1):247–54.PubMedPubMedCentralCrossRefGoogle Scholar
  508. Wititsuwannakul D, Kim KH. Mechanism of palmityl coenzyme A inhibition of liver glycogen synthase. J Biol Chem. 1977;252(21):7812–7.PubMedGoogle Scholar
  509. Woods SC, Lotter EC, McKay LD, Porte D Jr. Chronic intracerebroventricular infusion of insulin reduces food intake and body weight of baboons. Nature. 1979;282(5738):503–5.PubMedCrossRefGoogle Scholar
  510. Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev. 2011;91(2):733–94.CrossRefGoogle Scholar
  511. Xiang AH, Peters RK, Kjos SL, et al. Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes. 2006;55:517–22.PubMedPubMedCentralCrossRefGoogle Scholar
  512. Yang W, Weng J. Diabetes in Chian 3. Early therapy for type 2 diabetes in China. Lancet Diabetes Endocrinol. 2014;2:992–1002.PubMedCrossRefGoogle Scholar
  513. Yki-Jarvinen H. Pathogenesis of nonalconolic fatty liver disease. In: DeFronzo RA, Ferrannini E, Zimmet P, Alberti KGMM, editors. International textbook of diabetes mellitus. 4th ed. Chchester: Wiley; 2015. p. 283–91.Google Scholar
  514. Yki-Jarvinen H, DA MC. Glucotoxicity. In: DeFronzo RA, Ferrannini E, Zimmet P, Alberto KGMM, editors. International textbook of diabetes mellitus. 4th ed. Chichester: Wiley; 2015. p. 413–25.CrossRefGoogle Scholar
  515. Yki-Jarvinen H, Mott D, Young AA, et al. Regulation of glycogen synthase and phosphorylase activity by glucose and insulin in human skeletal muscle. J Clin Investig. 1987;80:95–100.PubMedCrossRefGoogle Scholar
  516. Yki-Jarvinen H, Daniels MC, Virkamaki A, Makimattila S, DeFronzo RA, McClain D. Increased glutamine:fructose-6-phosphate amidotransferase activity in skeletal muscle of patients with NIDDM. Diabetes. 1996;45(3):302–7.PubMedCrossRefGoogle Scholar
  517. Yoneda S, Uno S, Iwahashi H, et al. Predominance of beta-cell neogenesis rather than replication in humans with an impaired glucose tolerance and newly diagnosed diabetes. J Clin Endocrinol Metab. 2013;98(5):2053–61.PubMedCrossRefGoogle Scholar
  518. Yoon KH, Ko SH, Cho JH, et al. Selective beta-cell loss and alpha-cell expansion in patients with type 2 diabetes mellitus in Korea. J Clin Endocrinol Metab. 2003;88(5):2300–8.PubMedCrossRefGoogle Scholar
  519. Yu C, Cline GW, Zhang D, Zong H, Wang Y, Bergeron R, Kim JK, CushmanSW CGJ, Atcheson B, White MF, Kraegen EW, Shulman GI. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem. 2002;277:50230–6.PubMedCrossRefGoogle Scholar
  520. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet. 2002;359:824–30.CrossRefGoogle Scholar
  521. Zhang W, Liu J, Tian L, Liu Q, Fu Y, Garvey WT. TRIB3 mediates glucose-induced insulin resistance via a mechanism that requires the hexosamine biosynthetic pathway. Diabetes. 2013;62(12):4192–200.PubMedPubMedCentralCrossRefGoogle Scholar
  522. Zierath JR, He L, Guma A, et al. Insulin action on glucose transport and plasma membrane GLUT4 content in skeletal muscle from patients with NIDDM. Diabetologia. 1996;39:1180–9.PubMedCrossRefGoogle Scholar
  523. Zierler KL, Rabinowitz D. Roles of insulin and growth hormone, based on studies of forearm metabolism in man. Medicine. 1963;42:385–402.PubMedCrossRefGoogle Scholar
  524. Zimmet P, Whitehouse S, Alford F, Chisholm D. The relationship of insulin response to a glucose stimulus over a wide range of glucose tolerance. Diabetologia. 1978;15:23–7.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Diabetes Division, Diabetes Research UnitUniversity of Texas Health Science CenterSan AntonioUSA

Personalised recommendations